



(51) International Patent Classification:

C07D 257/04 (2006.01) *A61K 31/4245* (2006.01)
C07D 271/06 (2006.01) *A61P 25/00* (2006.01)
A61K 31/41 (2006.01)

(21) International Application Number:

PCT/US2013/051744

(22) International Filing Date:

23 July 2013 (23.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/675,753 25 July 2012 (25.07.2012) US

(71) Applicant: SOVA PHARMACEUTICALS, INC.
[US/US]; 11099 N. Torrey Pines Road, Suite 290, La Jolla,
CA 92037 (US).(72) Inventors: DURÓN, Sergio, G.; 1615 Neale Street, San
Diego, CA 92103 (US). CHAPMAN, Justin; 3436 Petra
Place, San Diego, CA 92104 (US). SYDSERFF, Simon,
G.; 17947 Pueblo Vista Lane, San Diego, CA 92127 (US).
RAO, Srinivas, G.; 1477 Paseo De Las Flores, Encinitas,
CA 92024 (US). STEIN, Gregory; 3790 Quarter Mile
Drive, San Diego, CA 92130 (US).(74) Agent: HOSTETLER, Michael, J.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA
94304 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CYSTATHIONINE- γ -GAMMA-LYASE (CSE) INHIBITORS

Fig. 10 CSE Target Engagement



(57) Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine- γ -lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

CYSTATHIONINE- γ -LYASE (CSE) INHIBITORS**CROSS-REFERENCE**

[0001] This application claims the benefit of U.S. Application No. 61/675,753, filed July 25, 2012, which is incorporated by reference in its entirety.


BACKGROUND OF THE INVENTION

[0002] Hydrogen sulfide (H_2S) is a recognized endogenous gasotransmitter involved in multiple signaling pathways that impact various aspects of physiological and pathological processes. Such processes include, but are not limited to; pain, inflammation, neurodegenerative disorders, regulation of breathing, respiratory disorders, cutaneous injuries, regulation of blood pressure, metabolic disorders, and urinary disorders, among others. Cystathionine- γ -lyase (CSE) is a key enzyme involved in the generation of H_2S and an important target for therapeutic intervention in H_2S -mediated pathologies and disorders. Compounds that can effectively modulate CSE activity will provide important therapeutic opportunities in disorders sensitive to H_2S production.

SUMMARY OF THE INVENTION

[0003] Described herein are inhibitors of cystathionine- γ -lyase (CSE). Also disclosed herein are methods for synthesizing such CSE inhibitors and methods for using such CSE inhibitors in the treatment of diseases wherein CSE inhibition provides therapeutic benefit to the patient having the disease. Further described are pharmaceutical formulations that include a CSE inhibitor.

[0004] In one aspect are compounds having the structure of Formula (I):



Formula (I);

wherein:

A is a carboxylic acid isostere;


X is CR_1 , or N ;

R_1 is H , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R_2 and R_3 are each independently H , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R_2 and R_3 together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0005] In another aspect are compounds having the structure of Formula (II):



Formula (II);

wherein:

A is a carboxylic acid isostere;


X is CR₁, or N;

R₁ is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0006] In another aspect are compounds having the structure of Formula (III):



Formula (III);


wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0007] In another aspect are compounds having the structure of Formula (IV):



Formula (IV);

wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0008] Provided herein, in some embodiments, are methods of treating or preventing or reducing the incidence of acute kidney injury (AKI) secondary to a toxic agent (e.g., cisplatin, aminoglycosides, and radiologic contrast material), nociceptive pain, acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, mixed neuropathic pain and inflammatory pain states, rheumatoid arthritis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, acute pancreatitis, chronic pancreatitis, pain associated with acute pancreatitis, pain associated with chronic pancreatitis, migraine headache, gout, ankylosing spondylitis, systemic lupus erythematosus (SLE), system inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), asthma, chronic obstructive pulmonary disease (COPD), sensitive skin, acne, rosacea, contact dermatitis, or pain associated with cancer, in individuals in need thereof comprising administration of a therapeutically effective amount of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) to the individual in need thereof. In some embodiments the pain associated with cancer is associated with pancreatic cancer. In some embodiments the pain associated with cancer is associated with lung cancer. In some embodiments the pain associated with cancer is associated with prostate cancer. In some embodiments the pain associated with cancer is associated with breast cancer.

[0009] Also provided herein, in some embodiments, are methods of treating or preventing or reducing the incidence of acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, rheumatoid arthritis, osteoarthritis, or migraine headache, in individuals in need thereof comprising administration of a therapeutically effective amount of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) to the individual in need thereof.

[0010] Also provided herein, in some embodiments, are methods of treating or preventing or reducing the incidence of acute kidney injury (AKI) secondary to a toxic agent (e.g., cisplatin, aminoglycosides, and radiologic contrast material), nociceptive pain, acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, mixed neuropathic pain and inflammatory pain states, rheumatoid arthritis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, acute pancreatitis, chronic pancreatitis, pain associated with acute pancreatitis, pain associated with chronic pancreatitis, migraine headache, gout, ankylosing spondylitis, systemic lupus erythematosus (SLE), system inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), asthma, chronic obstructive pulmonary disease (COPD), sensitive skin, acne, rosacea, contact dermatitis, or pain associated with cancer, in individuals in need thereof comprising administration of a therapeutically effective amount of 2-aminopent-4-ynoic acid,

(S)-2-aminopent-4-ynoic acid, 2-amino-3-cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid to the individual in need thereof.

[0011] Also provided herein, in some embodiments, are methods of treating or preventing or reducing the incidence of acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, rheumatoid arthritis, osteoarthritis, or migraine headache, in individuals in need thereof comprising administration of a therapeutically effective amount of 2-aminopent-4-ynoic acid, (S)-2-aminopent-4-ynoic acid, 2-amino-3-cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid to the individual in need thereof.

[0012] In some of the aforementioned embodiments, the method further comprises administering a second agent selected from carbonic anhydrase inhibitors, cholinesterase inhibitors, adenosine inhibitors, progestational agents, opioid antagonists, central nervous system stimulants, selective serotonin reuptake inhibitors (SSRIs), dual 5-HT-NE reuptake inhibitors (SNRI's), antidepressants, antihypertensives, calcium channel antagonists, ACE inhibitors, respiratory stimulants, alpha-2 adrenergic agonists, gamma aminobutyric acid agonists, antiepileptic drugs, NSAIDs, steroids, and glutamate antagonists. In some embodiments, the method further comprises administering a second agent selected from acetazolamide, theophylline, progesterone, donepezil, naloxone, nicotine, paroxetine, protriptyline, metoprolol, cilazapril, propranolol, atenolol, hydrochlorothiazide, isradipine, spirapril, doxapram, clonidine, baclofen, sabeluzole, gabapentin, pregablin, and duloxetine.

[0013] In some of the aforementioned embodiments, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) inhibits or partially inhibits the activity of cystathionine-gamma-lyase (CSE). In some specific embodiments, the compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) that inhibits or partially inhibits the activity of CSE, directly or indirectly reduces the sensitization or direct activation of cation conductance channels (e.g., TRP, CaV, NaV, Katp ion channels) in an individual in need thereof. In some specific embodiments, the compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) that inhibits or partially inhibits the activity of CSE reduces the sensitization or direct activation of cation conductance channels (e.g., TRP, CaV, NaV, Katp ion channels) improving hyperalgesia in an individual in need thereof. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), or (VI) that inhibits or partially inhibits the activity of cystathionine- γ -lyase (CSE) is administered orally, subcutaneously, topically, intramuscularly, or intravenously.

[0014] In some of the aforementioned embodiments, 2-aminopent-4-ynoic acid, (S)-2-aminopent-4-ynoic acid, 2-amino-3-cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid inhibits or partially inhibits the activity of cystathionine-gamma-lyase (CSE). In some specific embodiments, 2-aminopent-4-ynoic acid, (S)-2-aminopent-4-ynoic acid, 2-amino-3-

cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid, directly or indirectly reduces the sensitization or direct activation of cation conductance channels (e.g., TRP, CaV, NaV, Katp ion channels) in an individual in need thereof.

[0015] In some specific embodiments, 2-aminopent-4-ynoic acid, (S)-2-aminopent-4-ynoic acid, 2-amino-3-cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid reduces the sensitization or direct activation of cation conductance channels (e.g., TRP, CaV, NaV, Katp ion channels) improving hyperalgesia in an individual in need thereof. In some embodiments, 2-aminopent-4-ynoic acid, (S)-2-aminopent-4-ynoic acid, 2-amino-3-cyanopropanoic acid, or (S)-2-amino-3-cyanopropanoic acid is administered orally, subcutaneously, topically, intramuscularly, or intravenously.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Fig. 1 shows a graph of L-propargyl glycine (L-PAG), 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; in the Brennan Thermal Hyperalgesia model (Example 2).

[0017] Fig. 2 shows a graph of L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; and AMG-517; 3 mpk oral in the CCI Tactile Allodynia model (Example 3a).

[0018] Fig. 3 shows a graph of L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; and AMG-517; 3 mpk oral in the CCI Thermal Hyperalgesia model (Example 3a).

[0019] Fig. 4 shows a graph of L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; and AMG-517; 3 mpk oral in the CCI Tactile Hyperalgesia model (Example 3a).

[0020] Fig. 5 shows a graph of L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; and AMG-517; 3 mpk oral in the CFA Tactile Allodynia model (Example 4a).

[0021] Fig. 6 shows a graph of L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; and AMG-517; 3 mpk oral in the CFA Thermal Hyperalgesia model (Example 4a).

[0022] Fig. 7 shows a graph of Compound A (Cmpd A), 1, 10, 100 mpk oral; and Gabapentin; 300 mpk oral in the CCI Tactile Allodynia model (Example 3b).

[0023] Fig. 8 shows a graph of Compound A (Cmpd A), 1, 10, 100 mpk oral; and Naproxen; 30 mpk oral in the CFA Tactile Allodynia model (Example 4b).

[0024] Fig. 9 shows a graph of Compound A (Cmpd A), 1, 10, 100 mpk oral; and Gabapentin; 300 mpk oral in the MIA Tactile Allodynia model (Example 5).

[0025] Fig. 10 shows a graph of target engagement of Compound A (Cmpd A), 1, 3, 10, 30 mpk oral; in the CSE inhibition assay (Example 6).

[0026] Fig. 11 shows a graph of duration of effect of Compound A (Cmpd A), 30 mpk oral; in the CSE inhibition assay (Example 6).

DETAILED DESCRIPTION OF THE INVENTION

[0027] A devastating health problem in the United States and abroad is the inadequate treatment of pain. Pain can be acute or chronic and can also be categorized as nociceptive,

pathologic/neuropathic, or inflammatory pain. While acute pain is usually self-limited, chronic pain persists for three months or longer. One third of all Americans suffer from some form of chronic pain, and a third of these have pain, which is resistant to current medical therapy. The economic impact of pain is equally large at approximately \$100 billion annually. Severe pain syndromes reduce quality of life in patients, partly because reduced analgesic effectiveness with chronic opiate therapy (i.e., hyperalgesia and tolerance) leads to escalating doses and distressing side effects.

[0028] Neuropathic pain is a particular type of chronic, pathologic pain that has a complex and variable etiology. It is frequently a chronic condition attributable to complete or partial transection of a nerve, trauma or injury to a nerve, nerve plexus or soft tissue, or other conditions, including cancer and idiopathic causes. Neuropathic pain is characterized by hyperalgesia (lowered pain threshold and enhanced pain perception) and by allodynia (pain from innocuous mechanical or thermal stimuli). The condition is progressive in nature. Because the hyperesthetic component of neuropathic pain does not respond to the same pharmaceutical interventions as does more generalized and acute forms of pain, development of effective long-term treatment modalities has been problematic.

[0029] The treatment of pain is of great importance in medicine. However, little progress has been made in preventing the development of neuropathic pain, inflammatory pain and hyperalgesia. Thus, there is a serious need for new agents and methods of treating pain conditions.

[0030] Endogenous hydrogen sulfide is synthesized through degradation of L-cysteine by cystathionine-gamma-lyase (CSE) or cystathionine-beta synthase (CBS). The enzyme cystathionine-γ-lyase (CSE) converts cystathionine to L-cysteine, yielding pyruvate, ammonia and hydrogen sulfide. Hydrogen sulfide (H₂S) is a gasotransmitter physiologically regulating neuronal transmission and vascular tone. CBS is the predominant H₂S synthesizing enzyme in the brain, while CSE preponderates in the peripheral tissues.

[0031] Hydrogen sulfide in some embodiments is known to play a role in nociception by sensitizing or directly activating various ion channels (e.g., TRPV channels, TRPA1, NaV and CaV cation channels) potentially contributing to hyperalgesia as well as many other physiological processes including vasodilation (e.g., smooth muscle relaxation and/or opening of vascular smooth muscle K channels), and neuromodulation (e.g., induction of hippocampal long-term potentiation). Studies have shown that hydrogen sulfide is also associated with inflammation (e.g., hindpaw edema), acute pancreatitis, endotoxemia and sepsis.

Neuropathic pain

[0032] Disclosed herein, in certain embodiments, are methods of treating neuropathic pain in an individual in need thereof. Neuropathic pain is a complex, chronic, pathologic pain state that

may or may not be accompanied by an active tissue injury process. With neuropathic pain, the nerve fibers themselves may be damaged, dysfunctional or injured. These damaged nerve fibers send incorrect signals to other pain centers, potentially resulting in altered functioning at the level of the central nervous system. The impact of nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury.

[0033] One example of neuropathic pain is called phantom limb syndrome. This occurs when an arm or a leg has been removed because of illness or injury, but the brain still gets pain messages from the nerves that originally carried impulses from the missing limb. These nerves now misfire and cause pain.

[0034] Other examples of neuropathic pain include, but are not limited to, trigeminal neuralgia, painful diabetic peripheral neuropathy, sciatica, and post-herpetic neuralgia. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain. In trigeminal neuralgia, even mild stimulation of the face, such as from brushing teeth or putting on makeup, may trigger a jolt of excruciating pain.

[0035] Trigeminal neuralgia can occur as short, mild attacks, however, trigeminal neuralgia can also progress, causing longer, more frequent bouts of searing pain. Trigeminal neuralgia affects women more often than men, and it's more likely to occur in people who are older than 50.

[0036] Medications to lessen or block the pain signals sent to the brain are the most common initial treatment for trigeminal neuralgia. Anticonvulsants such as carbamazepine can be prescribed to treat trigeminal neuralgia. Carbamazepine (Tegretol, Carbatrol) is the drug most commonly prescribed, and with the most demonstrated effectiveness, for trigeminal neuralgia. Other anticonvulsant drugs used to treat trigeminal neuralgia include oxcarbazepine (Trileptal), lamotrigine (Lamictal), phenytoin (Dilantin, Phenytek) and gabapentin (Neurontin).

[0037] Antispasmodic agents can also be used to treat trigeminal neuralgia. Muscle-relaxing agents such as baclofen may be used alone or in combination with carbamazepine or phenytoin. Side effects may include confusion, nausea and drowsiness.

[0038] Alcohol injections provide temporary pain relief by numbing the affected areas of the face. Typically, alcohol is injected into the part of the face corresponding to the trigeminal nerve branch causing pain. The pain relief isn't permanent, so repeated injections or a different procedure in the future may be needed. Side effects may include infections at the injection site, bleeding and damage to nearby nerves.

[0039] Surgery is another option for the treatment of trigeminal neuralgia. The goal of surgery for trigeminal neuralgia is either to stop the blood vessel from compressing the trigeminal nerve or to damage the trigeminal nerve to keep it from malfunctioning. Damaging the nerve often causes temporary or permanent facial numbness, and with any of the surgical procedures, the pain can return months or years later.

[0040] Surgical options for trigeminal neuralgia include gamma-knife radiosurgery (GKR); and microvascular decompression (MVD). GKR involves delivering a focused, high dose of radiation to the root of the trigeminal nerve. Because of GKR's effectiveness and safety compared with other surgical options for trigeminal neuralgia, the procedure is becoming widely used and may be offered earlier than other surgical procedures.

[0041] Gamma-knife radiosurgery uses radiation to damage the trigeminal nerve and reduce or eliminate pain. Relief occurs gradually and can take several weeks to begin. GKR is successful in eliminating pain for the majority of people. If pain recurs, the procedure can be repeated. Fewer than 5 percent of people who undergo this procedure experience side effects, which may include lasting loss of facial sensation. The procedure is painless and typically is done without anesthesia.

[0042] Microvascular decompression (MVD) involves relocating or removing blood vessels that are in contact with the trigeminal root. During MVD, the doctor makes an incision behind the ear on the side of the pain. Then, through a small hole in the skull, part of the brain is lifted to expose the trigeminal nerve. Any artery in contact with the nerve root is directed away from the nerve, and the surgeon places a pad between the nerve and the artery. If a vein is compressing the nerve, the surgeon typically will remove it.

[0043] MVD can successfully eliminate or reduce pain most of the time, but pain can recur in some people. While MVD has a high success rate, it also carries risks. There are small chances of decreased hearing, facial weakness, facial numbness, double vision, and even a stroke or death. Most people who have this procedure have no facial numbness afterward.

[0044] Note that if no artery or vein appears to be compressing the nerve, part of the nerve may be severed instead. This procedure is called a rhizotomy.

[0045] During glycerol injection, a needle is inserted through the face and into an opening in the base of the skull. The needle is guided into the trigeminal cistern, a small sac of spinal fluid that surrounds the trigeminal nerve ganglion, where the trigeminal nerve divides into three branches, and part of its root. Images are made to confirm that the needle is in the proper location, and then a small amount of sterile glycerol is injected. After three or four hours, the glycerol damages the trigeminal nerve and blocks pain signals. Initially, this procedure relieves pain in most people. However, some people have a later recurrence of pain, and many experience facial numbness or tingling.

[0046] In balloon compression of the trigeminal nerve, a hollow needle is inserted through the face and into an opening in the base of the skull. Then, a thin, flexible tube (catheter) with a balloon on the end is threaded through the needle. The balloon is inflated with enough pressure to damage the nerve and block pain signals. Balloon compression successfully controls pain in

most people, at least for a while. Most people undergoing this procedure experience some facial numbness, and some experience temporary or permanent weakness of the muscles used to chew.

[0047] Electric current (radiofrequency thermal rhizotomy) selectively destroys nerve fibers associated with pain. A hollow needle is placed through the face and into an opening in the skull. Once the needle is positioned, an electrode is threaded through it to the nerve root. Then the electrode is heated until it damages the nerve fibers, creating an area of injury (lesion). If the pain isn't eliminated, additional lesions may be created. Almost everyone who undergoes radiofrequency thermal rhizotomy has some facial numbness after the procedure.

[0048] A procedure called partial trigeminal rhizotomy involves cutting part of the trigeminal nerve at the base of the brain. Through an incision behind an ear, a quarter-sized hole is made in the skull to access the nerve. Because partial trigeminal rhizotomy cuts the nerve at its source, facial numbness is a permanent side effect.

[0049] Diabetic neuropathies are neuropathic disorders that are associated with diabetes mellitus. These conditions are thought to result from diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum) in addition to macrovascular conditions that can culminate in diabetic neuropathy. Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy.

[0050] Despite advances in the understanding of the metabolic causes of neuropathy, treatments aimed at interrupting these pathological processes have been limited. Thus, with the exception of tight glucose control, treatments are for reducing pain and other symptoms.

[0051] Options for pain control include tricyclic antidepressants (TCAs), serotonin reuptake inhibitors (SSRIs) and antiepileptic drugs (AEDs). A systematic review concluded that "tricyclic antidepressants and traditional anticonvulsants are better for short term pain relief than newer generation anticonvulsants." A combination of these medications (gabapentin + nortriptyline) may also be superior to a single agent.

[0052] The two drugs approved by the FDA for diabetic peripheral neuropathy are the antidepressant duloxetine and the anticonvulsant pregabalin. Before trying a systemic medication, some doctors recommend treating localized diabetic peripheral neuropathy with lidocaine patches.

[0053] Postherpetic neuralgia (PHN) is a nerve pain due to damage caused by the varicella zoster virus. Typically, the neuralgia is confined to a dermatomic area of the skin and follows an outbreak of herpes zoster (HZ, commonly known as shingles) in that same dermatomic area. The neuralgia typically begins when the HZ vesicles have crusted over and begun to heal, but it can begin in the absence of HZ, in which case zoster sine herpete is presumed (see Herpes zoster).

[0054] Treatment options for PHN include antidepressants, anticonvulsants (such as gabapentin or pregabalin) and topical agents such as lidocaine patches or capsaicin lotion. Opioid analgesics may also be appropriate in many situations. There are some sporadically successful experimental treatments, such as rhizotomy (severing or damaging the affected nerve to relieve pain) and TENS (a type of electrical pulse therapy).

[0055] Neuropathic pain often seems to have no obvious cause; but, some common causes of neuropathic pain include alcoholism; amputation; back, leg, and hip problems; chemotherapy; diabetes; facial nerve problems; HIV infection or AIDS; multiple sclerosis; shingles; and spine surgery.

[0056] Symptoms may include shooting and burning pain; and tingling and numbness.

[0057] Some neuropathic pain studies suggest the use of non-steroidal anti-inflammatory drugs, such as Aleve or Motrin, may ease pain. Some people may require a stronger painkiller, such as those containing morphine. Anticonvulsant and antidepressant drugs seem to work in some cases.

[0058] If another condition, such as diabetes, is involved, better management of that disorder may alleviate the pain.

[0059] In cases that are difficult to treat, a pain specialist may use invasive or implantable device therapies to effectively manage the pain. Electrical stimulation of the nerves involved in neuropathic pain generation may significantly control the pain symptoms.

[0060] Unfortunately, neuropathic pain often responds poorly to standard pain treatments and occasionally may get worse instead of better over time. For some people, it can lead to serious disability.

[0061] Disclosed herein, in certain embodiments, are methods of treating neuropathic pain in an individual in need thereof. In some embodiments, the neuropathic pain is trigeminal neuralgia. In some embodiments, the neuropathic pain is diabetic peripheral neuropathy. In some embodiments, the neuropathic pain is herpetic neuralgia. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Pain associated with a disease or condition

[0062] Disclosed herein, in certain embodiments, are methods of treating pain associated with a disease or condition in an individual in need thereof. In some embodiments, the disease or condition is an autoimmune disease. In some instances, the autoimmune disease is rheumatoid arthritis. In some embodiments, the autoimmune disease is lupus. In some embodiments, the autoimmune disease is systemic lupus erythematosus. In some embodiments, the disease or

condition is an inflammatory disease. In some instances, the inflammatory disease is pancreatitis, acute pancreatitis, or chronic pancreatitis. In some embodiments, the inflammatory disease is asthma. In some instances, the inflammatory disease is arthritis. In some instances, the inflammatory disease is osteoarthritis. In some instances, the inflammatory disease is gout. In some instances, the inflammatory disease is rheumatoid arthritis. In some instances, the inflammatory disease is ankylosing spondylitis. In some instances, the inflammatory disease is inflammatory bowel disease or irritable bowel syndrome. In some embodiments, the disease or condition is a cancer. In some embodiments, the cancer is a carcinoma, sarcoma, melanoma, lymphoma, or leukemia. In some embodiments, the cancer is a pancreatic cancer, lung cancer, prostate cancer, brain cancer, intestinal cancer, throat cancer, colon cancer, and breast cancer. In some instances, the disease or condition is a lung disease. . In some instances, the lung disease is chronic obstructive pulmonary disease. In some instances, the lung disease is chronic bronchitis. In some embodiments, the lung disease is emphysema. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Acute Post-Operative Pain

[0063] Disclosed herein, in certain embodiments, are methods of preventing or reducing acute post-operative pain in an individual in need thereof. Post-operative pain (as a result of surgery) is usually considered normal. However, when poorly controlled, the pain can cause increased heart and respiratory rate, anxiety, nausea and vomiting, urinary retention, and elevated adrenalin and cortisol levels, or reduced immune response and increased risk of infection.

[0064] Uncontrolled pain is similar to uncontrolled fear in that it promotes a "fight or flight" reaction. This reaction tends to delay wound healing and increases the complication rate including infection.

[0065] Education as to the nature of the surgery or procedure is very important in order to minimize fear and anxiety pre-operatively.

[0066] The following have all been shown to reduce post-operative pain and surgical infection, and hasten wound healing use of non-steriod anti-inflammatories, such as ibuprofen preoperatively; injection of local anesthetic into the wound prior to suturing; more liberal prescription of post-operative analgesics; and use of intra- and post-operative epidural infusions for complex surgeries. Numerous studies also demonstrate the effectiveness of relaxation techniques, such as hypnosis and massage therapy in reducing post-operative pain.

[0067] Disclosed herein, in certain embodiments, are methods of preventing or reducing acute post-operative pain in an individual in need thereof. In some embodiments, the methods

comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor in combination with non-steroid anti-inflammatories. In some embodiments, the methods comprise administering a CSE inhibitor in combination with ibuprofen. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a local anesthetic. In some embodiments, the methods comprise administering a CSE inhibitor in combination with an epidural infusion.

Organ Maintenance

[0068] Disclosed herein, in certain embodiments, are methods of preventing or reducing the incidence of acute kidney injury (AKI) secondary to a toxic agent (e.g., cisplatin, aminoglycosides, and radiologic contrast material) in an individual in need thereof. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

[0069] Disclosed herein, in certain embodiments, are methods of preventing multi-organ dysfunction syndrome (MODS). In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Autoimmune Disease

[0070] Disclosed herein, in certain embodiments, are methods of treating an autoimmune disease in an individual in need thereof. Autoimmune diseases often arise from an inappropriate immune response of the body against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (e.g. in autoimmune thyroiditis) or involve a particular tissue in different places (e.g. Goodpasture's disease which may affect the basement membrane in both the lung and the kidney). The treatment of autoimmune diseases is typically with immunosuppression—medication which decreases the immune response.

[0071] Examples of autoimmune diseases include, but are not limited to, acute disseminated encephalomyelitis (ADEM), Addison's disease, agammaglobulinemia, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, antiphospholipid syndrome, antisyntetase syndrome, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune enteropathy, autoimmune hemolytic anemia, autoimmune

hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Balo disease/Balo concentric sclerosis, Behçet's disease, Berger's disease, Bickerstaff's encephalitis, Blau syndrome, Bullous pemphigoid, Castleman's disease, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, chronic recurrent multifocal osteomyelitis, chronic obstructive pulmonary disease, Churg-Strauss syndrome, cicatricial pemphigoid, Cogan syndrome, cold agglutinin disease, complement component 2 deficiency, contact dermatitis, cranial arteritis, CREST syndrome, Crohn's disease (one of two types of idiopathic inflammatory bowel disease "IBD"), Cushing's Syndrome, cutaneous leukocytoclastic angiitis, Dego's disease, Dercum's disease, dermatitis herpetiformis, dermatomyositis, diabetes mellitus type 1, diffuse cutaneous systemic sclerosis, Dressler's syndrome, drug-induced lupus, discoid lupus erythematosus, eczema, endometriosis, enthesitis-related arthritis, eosinophilic fasciitis, eosinophilic gastroenteritis, epidermolysis bullosa acquisita, erythema nodosum, erythroblastosis fetalis, essential mixed cryoglobulinemia, Evan's syndrome, fibrodysplasia ossificans progressive, fibrosing alveolitis (or idiopathic pulmonary fibrosis), gastritis, gastrointestinal pemphigoid, giant cell arteritis, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's encephalopathy, Hashimoto's thyroiditis, Henoch-Schönlein purpura, herpes gestationis (aka gestational pemphigoid), hidradenitis suppurativa, Hughes-Stovin syndrome, hypogammaglobulinemia, idiopathic inflammatory demyelinating diseases, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, IgA nephropathy, inclusion body myositis, chronic inflammatory demyelinating polyneuropathy, interstitial cystitis, juvenile idiopathic arthritis aka juvenile rheumatoid arthritis, Kawasaki's disease, Lambert-Eaton myasthenic syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, linear IgA disease (LAD), Lou Gehrig's disease (aka amyotrophic lateral sclerosis), lupoid hepatitis (aka Autoimmune hepatitis), lupus erythematosus, Majeed syndrome, Ménière's disease, microscopic polyangiitis, Miller-Fisher syndrome see Guillain-Barre Syndrome, mixed connective tissue disease, morphea, Mucha-Habermann disease (aka Pityriasis lichenoides et varioliformis acuta), multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (also Devic's disease), neuromyotonia, ocular cicatricial pemphigoid, opsoclonus myoclonus syndrome, Ord's thyroiditis, palindromic rheumatism, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonage-Turner syndrome, Pars planitis, pemphigus vulgaris, pernicious anaemia, perivenous encephalomyelitis, POEMS syndrome, polyarteritis nodosa, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis,

primary sclerosing cholangitis, progressive inflammatory neuropathy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, pure red cell aplasia, Rasmussen's encephalitis, Raynaud phenomenon, relapsing polychondritis, Reiter's syndrome, restless leg syndrome, retroperitoneal fibrosis, rheumatoid arthritis, rheumatic fever, sarcoidosis, schizophrenia, Schmidt syndrome, Schnitzler syndrome, scleritis, scleroderma, serum sickness, Sjögren's syndrome, spondyloarthropathy, Still's disease, stiff person syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, Sweet's syndrome, Sydenham chorea, sympathetic ophthalmia, systemic lupus erythematosus, Takayasu's arteritis, temporal arteritis (also known as "giant cell arteritis"), thrombocytopenia, Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis (one of two types of idiopathic inflammatory bowel disease "ibd"), undifferentiated connective tissue disease different from mixed connective tissue disease, undifferentiated spondyloarthropathy, urticarial vasculitis, vasculitis, vitiligo, and Wegener's granulomatosis.

[0072] Disclosed herein, in certain embodiments, are methods of treating an autoimmune disease in an individual in need thereof. In some instances, the autoimmune disease is rheumatoid arthritis. In some embodiments, the autoimmune disease is lupus. In some embodiments, the autoimmune disease is systemic lupus erythematosus. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Inflammatory Disease

[0073] Disclosed herein, in certain embodiments, are methods of treating an inflammatory disease in an individual in need thereof. Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli and to initiate the healing process. Inflammation is not a synonym for infection, even in cases where inflammation is caused by infection. Although infection is caused by a microorganism, inflammation is one of the responses of the organism to the pathogen. However, inflammation is a stereotyped response, and therefore it is considered as a mechanism of innate immunity, as compared to adaptive immunity, which is specific for each pathogen.

[0074] Without inflammation, wounds and infections would never heal. Similarly, progressive destruction of the tissue would compromise the survival of the organism. However, chronic inflammation can also lead to a host of diseases, such as hay fever, periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer (e.g., gallbladder carcinoma). It is for that reason that inflammation is normally closely regulated by the body.

[0075] Inflammation can be classified as either acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes (especially granulocytes) from the blood into the injured tissues. A cascade of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process.

[0076] Inflammatory abnormalities are a large group of disorders which underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with etiological origins in inflammatory processes include cancer, atherosclerosis, and ischaemic heart disease. A large variety of proteins are involved in inflammation, and any one of them is open to a genetic mutation which impairs or otherwise dysregulates the normal function and expression of that protein.

[0077] Examples of disorders associated with inflammation include, but are not limited to, acne vulgaris, asthma, autoimmune diseases, celiac disease, chronic prostatitis, glomerulonephritis, hypersensitivities, inflammatory bowel diseases, pelvic inflammatory disease, primary or secondary pulmonary fibrosis, chronic obstructive pulmonary disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis and interstitial cystitis. Types of inflammation include, but are not limited to, appendicitis, bursitis, colitis, cystitis, dermatitis, meningitis, phlebitis, rhinitis, tendonitis, and tonsillitis

[0078] Disclosed herein, in certain embodiments, are methods of treating an inflammatory disease in an individual in need thereof. In some embodiments, the disease or condition is an inflammatory disease. In some instances, the inflammatory disease is pancreatitis, acute pancreatitis, or chronic pancreatitis. In some embodiments, the inflammatory disease is asthma. In some instances, the inflammatory disease is arthritis. In some instances, the inflammatory disease is osteoarthritis. In some instances, the inflammatory disease is gout. In some instances, the inflammatory disease is rheumatoid arthritis. In some instances, the inflammatory disease is ankylosing spondylitis. In some instances, the inflammatory disease is inflammatory bowel disease or irritable bowel syndrome. In some embodiments, the inflammatory disease is system inflammatory response syndrome (SIRS). In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the

methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Headache

[0079] Disclosed herein, in certain embodiments, are methods of treating a headache in an individual in need thereof. Disclosed herein, in certain embodiments, are methods of treating a migraine headache in an individual in need thereof. Disclosed herein, in certain embodiments, are methods of treating a simple migraine headache in an individual in need thereof. Disclosed herein, in certain embodiments, are methods of treating a complicated migraine headache in an individual in need thereof. Disclosed herein, in certain embodiments, are methods of treating a tension headache in an individual in need thereof. Disclosed herein, in certain embodiments, are methods of treating a cluster headache in an individual in need thereof. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Stroke

[0080] A stroke is the rapid loss of brain function(s) due to disturbance in the blood supply to the brain. In an ischemic stroke, blood supply to part of the brain is decreased, leading to dysfunction of the brain tissue in that area. Current evidence suggests that H₂S promotes ischemic damage by a direct degenerative effect on cerebral neurons, although effect on cerebral blood flow may not be excluded.

[0081] Disclosed herein, in certain embodiments, are methods of treating stroke in an individual in need thereof. In some embodiments, the methods comprise administering a CSE inhibitor. In some embodiments, the methods comprise administering a CSE inhibitor in combination with a second treatment regimen. In some embodiments, the methods comprise administering a CSE inhibitor before, simultaneously with, or after a second treatment regimen.

Definitions

[0082] As used herein, the terms “treat,” “treating” or “treatment,” include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, preventing progression of the condition, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition. In one embodiment, treatment is prophylactic treatment. In another embodiment, treatment refers to therapeutic treatment.

[0083] As used herein, “administer” means to provide a treatment, for example to prescribe a treatment, apply a treatment, or distribute a treatment. In some instances, to administer means a

medical professional prescribes a treatment which a patient applies (e.g., the patient applies a CPAP device, consumes a medication, or injects a medication). Administration of a medical treatment does not require the immediate or constant supervision of a medical professional.

[0084] “Co-administration” or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.

[0085] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.

[0086] The term “subject” or “patient” encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one embodiment, the mammal is a human.

[0087] A “tissue” comprises two or more cells. The two or more cells may have a similar function and/or function. The tissue may be a connective tissue, epithelial tissue, muscular tissue, or nervous tissue. Alternatively, the tissue is a bone, tendon (both referred to as musculoskeletal grafts), cornea, skin, heart valve, or vein.

[0088] An “organ” comprises two or more tissues. The two or more tissues may perform a specific function or group of functions. In some instances, the organ is a lung, mouth, nose, parathyroid gland, pineal gland, pituitary gland, carotid body, salivary gland, skin, gall bladder, pancreas, small intestine, stomach, spleen, spinal cord, thymus, thyroid gland, trachea, uterus, or vermiform appendix. Alternatively, the organ is an adrenal gland, appendix, brain, bladder, kidney, intestine, large intestine, small intestine, liver, heart, or muscle.

[0089] The term “CSE inhibitor” encompasses a full or partial inhibitor of CSE enzymatic activity in the synthesis of hydrogen sulfide.

[0090] “Activity of the carotid body” refers to the response of the carotid body to various signals. In some embodiments, such signals include $p\text{CO}_2$ or $p\text{O}_2$ in arterial blood. In some embodiments, such signals include presence or absence of certain gasotransmitters such as CO

or H₂S in the carotid body or in the vicinity of the carotid body. In some embodiments, such signals include presence or absence of certain ions such as Ca²⁺ or K⁺ ions in the carotid body or in the vicinity of the carotid body. In some embodiments, such signals include action potentials of the nerves that innervate the carotid body.

[0091] “Chemosensitivity” of the carotid body refers to the magnitude of the response of the carotid body to a known level of stimulation by chemical messengers including and not limited to O₂, CO₂, CO, and H₂S. Increased chemosensitivity is defined as an increased and disproportionate response to one that is observed under normal physiologic conditions to a similar stimulus.

[0092] The term “optionally substituted” or “substituted” means that the referenced group substituted with one or more additional group(s). In certain embodiments, the one or more additional group(s) are individually and independently selected from amide, ester, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, ester, alkylsulfone, arylsulfone, cyano, halogen, alkoyl, alkoyloxo, isocyanato, thiocyanato, isothiocyanato, nitro, haloalkyl, haloalkoxy, fluoroalkyl, amino, alkyl-amino, dialkyl-amino, amido. In one embodiment, the referenced group is substituted with one or more halogen. In another embodiment, the referenced group is substituted with one or more alkyl.

[0093] An “alkyl” group refers to an aliphatic hydrocarbon group. Reference to an alkyl group includes “saturated alkyl” and/or “unsaturated alkyl”. The alkyl group, whether saturated or unsaturated, includes branched, straight chain, or cyclic groups. By way of example only, alkyl includes methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, pentyl, iso-pentyl, neo-pentyl, and hexyl. In some embodiments, alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. A “lower alkyl” is a C₁-C₆ alkyl. A “heteroalkyl” group substitutes any one of the carbons of the alkyl group with a heteroatom having the appropriate number of hydrogen atoms attached (e.g., a CH₂ group to an NH group or an O group).

[0094] An “alkoxy” group refers to a (alkyl)O- group, where alkyl is as defined herein.


[0095] The term “alkylamine” refers to the -N(alkyl)_xH_y group, wherein alkyl is as defined herein and x and y are selected from the group x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, taken together with the nitrogen to which they are attached, optionally form a cyclic ring system.

[0096] An “amide” is a chemical moiety with formula C(O)NHR or NHC(O)R, where R is selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon).

[0097] The term “ester” refers to a chemical moiety with formula $-C(=O)OR$, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic.

[0098] As used herein, the term “aryl” refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl rings described herein include rings having five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups are optionally substituted. Examples of aryl groups include, but are not limited to phenyl, and naphthalenyl.

[0099] The term “cycloalkyl” refers to a monocyclic or polycyclic non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. In various embodiments, cycloalkyls are saturated, or partially unsaturated. In some embodiments, cycloalkyls are fused with an aromatic ring. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:




the like. Monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Dicyclic cycloalkyls include, but are not limited to tetrahydronaphthyl, indanyl, tetrahydropentalene or the like. Polycyclic cycloalkyls include adamantane, norbornane or the like. The term cycloalkyl includes "unsaturated nonaromatic carbocyclyl" or "nonaromatic unsaturated carbocyclyl" groups both of which refer to a nonaromatic carbocycle, as defined herein, that contains at least one carbon carbon double bond or one carbon carbon triple bond.


[00100] The term “heterocyclo” refers to heteroaromatic and heteroalicyclic groups containing one to four ring heteroatoms each selected from O, S and N. In certain instances, each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Non-aromatic heterocyclic groups include groups having 3 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 3-membered heterocyclic group is aziridinyl (derived from aziridine). An example of a 4-membered heterocyclic group is azetidiny (derived from azetidine). An example of a 5-membered heterocyclic group is thiazolyl. An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10-membered heterocyclic group is quinolinyl. Examples






















of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, aziridinyl, azetidyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.

[00101] The terms “heteroaryl” or, alternatively, “heteroaromatic” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. An *N*-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. In certain embodiments, heteroaryl groups are monocyclic or polycyclic. Examples of monocyclic heteroaryl groups include and are not limited to:




[00102] Examples of bicyclic heteroaryl groups include and are not limited to:




quinoline
(quinolinyl)isoquinoline
(isoquinolinyl)cinnoline
(cinnolinyl)quinazoline
(azaquinazoline)quinoxaline
(quinoxalinyl)phthalazine
(phthalazinyl)1,6-naphthyridine
(1,6-naphthyridinyl)1,7-naphthyridine
(1,7-naphthyridinyl)1,8-naphthyridine
(1,8-naphthyridinyl)1,5-naphthyridine
(1,5-naphthyridinyl)2,6-naphthyridine
(2,6-naphthyridinyl)2,7-naphthyridine
(2,7-naphthyridinyl)pyrido[3,2-d]pyrimidine
(pyrido[3,2-d]pyrimidinyl)pyrido[4,3-d]pyrimidine
(pyrido[4,3-d]pyrimidinyl)pyrido[3,4-d]pyrimidine
(pyrido[3,4-d]pyrimidinyl)pyrido[2,3-d]pyrimidine
(pyrido[2,3-d]pyrimidinyl)pyrido[2,3-b]pyrazine
(pyrido[2,3-b]pyrazinyl)pyrido[3,4-b]pyrazine
(pyrido[3,4-b]pyrazinyl)pyrimido[5,4-d]pyrimidine
(pyrido[5,4-d]pyrimidinyl)pyrazino[2,3-b]pyrazine
(pyrazino[2,3-b]pyrazinyl)pyrimido[4,5-d]pyrimidine
(pyrido[4,5-d]pyrimidinyl) or the like.


[00103] A “heteroalicyclic” group or “heterocyclo” group or “heterocycloalkyl” group or “heterocyclyl” group refers to a cycloalkyl group, wherein at least one skeletal ring atom is a heteroatom selected from nitrogen, oxygen and sulfur. In various embodiments, heterocycloalkyls are saturated, or partially unsaturated. In some embodiments, the radicals are fused with an aryl or heteroaryl. Example of saturated heterocycloalkyl groups include




[00104] Examples of partially unsaturated heterocyclyl or heterocycloalkyl groups include



[00105] Other illustrative examples of heterocyclo or heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:





[00106] The term heteroalicyclic also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.

[00107] The term “halo” or, alternatively, “halogen” means fluoro, chloro, bromo and iodo.

[00108] The terms “haloalkyl,” and “haloalkoxy” include alkyl and alkoxy structures that are substituted with one or more halogens. In embodiments, where more than one halogen is included in the group, the halogens are the same or they are different. The terms “fluoroalkyl” and “fluoroalkoxy” include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.

[00109] The term “heteroalkyl” include optionally substituted alkyl, alkenyl and alkynyl radicals which have one or more skeletal chain atoms selected from an atom other than carbon, *e.g.*, oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. In certain embodiments, the heteroatom(s) is placed at any interior position of the heteroalkyl group. Examples include, but are not limited to, $-\text{CH}_2-\text{O}-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_3$, $-\text{CH}_2-\text{NH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_3$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{N}(\text{CH}_3)-\text{CH}_3$, $-\text{CH}_2-\text{S}-\text{CH}_2-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{S}(\text{O})-\text{CH}_3$, $-\text{CH}_2-\text{CH}_2-\text{S}(\text{O})_2-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{O}-\text{CH}_3$, $-\text{Si}(\text{CH}_3)_3$, $-\text{CH}_2-\text{CH}=\text{N}-\text{OCH}_3$, and $-\text{CH}=\text{CH}-\text{N}(\text{CH}_3)-\text{CH}_3$. In some embodiments, up to two heteroatoms are consecutive, such as, by way of example, $-\text{CH}_2-\text{NH}-\text{OCH}_3$ and $-\text{CH}_2-\text{O}-\text{Si}(\text{CH}_3)_3$.

[00110] A “cyano” group refers to a CN group.

[00111] An “isocyanato” group refers to a NCO group.

[00112] A “thiocyanato” group refers to a CNS group.


[00113] An “isothiocyanato” group refers to a NCS group.

[00114] “Alkoyloxy” refers to a $\text{RC}(=\text{O})\text{O}-$ group.

[00115] “Alkoyl” refers to a $\text{RC}(=\text{O})-$ group.

[00116] “Isosteres” of a chemical group are chemical groups that have different molecular formulae but exhibit the same or similar properties. For example, tetrazole is an isostere of carboxylic acid because it mimics the properties of carboxylic acid even though they both have very different molecular formulae. Tetrazole is one of many possible isosteric replacements for carboxylic acid. Other carboxylic acid isosteres contemplated include SO_3H , $-\text{SO}_2\text{NHR}_4$, $-\text{P}(\text{O})(\text{OR}_4)_2$, $-\text{P}(\text{O})(\text{R}_4)(\text{OR}_4)$, $-\text{CON}(\text{R}_4)_2$, $-\text{CONHNHSO}_2\text{R}_4$, $-\text{CONHSO}_2\text{R}_4$, $-\text{B}(\text{OR}_5)_2$, $-\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$, and $-\text{CON}(\text{R}_4)\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$; wherein each R_4 is independently H, OH,

substituted or unsubstituted alkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl. In addition, carboxylic acid isosteres can include 5-7 membered carbocycles or heterocycles containing any combination of CH₂, O, S, or N in any chemically stable oxidation state, where any of the atoms of said ring structure are optionally substituted in one or more positions. The following structures are non-limiting examples of preferred carbocyclic and heterocyclic isosteres contemplated.



[00117] It is also contemplated that when chemical substituents are added to a carboxylic acid isostere then the inventive compound retains the properties of a carboxylic acid isostere. The present invention contemplates that when a carboxylic acid isostere is optionally substituted, then the substitution cannot eliminate the carboxylic acid isosteric properties of the inventive compound. It is contemplated that the placement of one or more substituents upon a carbocyclic or heterocyclic carboxylic acid isostere is not a substitution at one or more atom(s) which maintain(s) or is/are integral to the carboxylic acid isosteric properties of the compound, if such substituent(s) would destroy the carboxylic acid isosteric properties of the compound.


[00118] Other carboxylic acid isosteres not specifically exemplified or described in this specification are also contemplated by the present invention.

CSE Inhibitors

[00119] In the following description of CSE inhibitory compounds suitable for use in the methods described herein, definitions of referred-to standard chemistry terms may be found in reference works (if not otherwise defined herein), including Carey and Sundberg "Advanced Organic Chemistry 4th Ed." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the ordinary skill of the art are employed. Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[00120] Described herein are compounds of any of Formula (I), (II), (IIa), (III), (IV), or (IVa). Also described herein are pharmaceutically acceptable salts, pharmaceutically acceptable solvates, and pharmaceutically acceptable prodrugs of such compounds. Pharmaceutical compositions that include at least one such compound or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug of such compound, are provided. In certain embodiments, isomers and chemically protected forms of compounds having a structure represented by any of Formula (I), (II), (IIa), (III), (IV), or (IVa) are also provided.

[00121] In one aspect are compounds having the structure of Formula (I):



Formula (I);

wherein:


A is a carboxylic acid isostere;

X is CR₁, or N;

R₁ is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R_2 and R_3 are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R_2 and R_3 together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00122] In another aspect are compounds having the structure of Formula (II):



Formula (II);

wherein:

A is a carboxylic acid isostere;


X is CR_1 , or N;


R_1 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R_2 and R_3 are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R_2 and R_3 together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00123] In some embodiments is a compound of Formula (I) or (II) wherein A is a carboxylic acid isostere selected from:





[00124] In some embodiments is a compound of Formula (I) or (II) wherein A is a carboxylic acid isostere selected from $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NHR}_4$, $-\text{P}(\text{O})(\text{OR}_4)_2$, $-\text{P}(\text{O})(\text{R}_4)(\text{OR}_4)$, $-\text{CON}(\text{R}_4)_2$, $-\text{CONHNHSO}_2\text{R}_4$, $-\text{CONHSO}_2\text{R}_4$, $-\text{B}(\text{OR}_5)_2$, $-\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$, and $-\text{CON}(\text{R}_4)\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$; wherein each R_4 is independently H, OH, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and R_5 is H or $\text{C}_1\text{-C}_6$ alkyl.

[00125] In some embodiments is a compound of Formula (I) or (II) wherein A is a carboxylic acid isostere selected from $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NHR}_4$, $-\text{P}(\text{O})(\text{OR}_4)_2$, $-\text{P}(\text{O})(\text{R}_4)(\text{OR}_4)$, $-\text{C}(\text{O})\text{NR}_4$, $-\text{CON}(\text{R}_4)_2$, $-\text{CONHNHSO}_2\text{R}_4$, $-\text{CONHSO}_2\text{R}_4$, $-\text{B}(\text{OR}_5)_2$, $-\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$, and $-\text{CON}(\text{R}_4)\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$; wherein each R_4 is independently H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl; and R_5 is H or $\text{C}_1\text{-C}_6$ alkyl.


[00126] In further embodiments is a compound of Formula (I) or (II) wherein X is CR_1 . In yet further embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. In some embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is H. In some embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is substituted or unsubstituted alkyl. In some embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is CH_3 . In yet further embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is substituted or unsubstituted heteroalkyl. In other embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is substituted or unsubstituted heterocycloalkyl. In some embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is substituted or unsubstituted aryl. In other embodiments is a compound of Formula (I) or (II) wherein X is CR_1 ; and R_1 is substituted or unsubstituted heteroaryl.


[00127] In some embodiments is a compound of Formula (I) or (II) wherein X is N.

[00128] In any of the aforementioned embodiments of Formula (I) or (II) is a compound wherein R_2 and R_3 are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. In any of the aforementioned embodiments of Formula (I) or (II) is a compound wherein R_2 and R_3 are each H. In any of the aforementioned of Formula (I) or (II) is a compound wherein R_2 and R_3 are each independently substituted or unsubstituted alkyl. In any


of the aforementioned embodiments of Formula (I) or (II) is a compound wherein R_2 and R_3 are each independently substituted or unsubstituted heteroalkyl. In any of the aforementioned

embodiments of Formula (I) or (II) is a compound wherein A is . In any of the

aforementioned embodiments of Formula (I) or (II) is a compound wherein A is . In any of the aforementioned embodiments of Formula (I) or (II) is a compound wherein A is



[00129] In another aspect are compounds having the structure of Formula (IIa):



Formula (IIa);

wherein:

A is a carboxylic acid isostere;


X is CR_1 , or N;


R_1 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R_2 and R_3 are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R_2 and R_3 together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00130] In some embodiments is a compound of Formula (I), (II), or (IIa) wherein A is a carboxylic acid isostere selected from:





[00131] In some embodiments is a compound of Formula (I), (II), or (IIa) wherein A is a carboxylic acid isostere selected from -SO₃H, -SO₂NHR₄, -P(O)(OR₄)₂, -P(O)(R₄)(OR₄), -CON(R₄)₂, -CONHNHSO₂R₄, -CONHSO₂R₄, -B(OR₅)₂, -C(R₄)₂B(OR₅)₂, and -CON(R₄)C(R₄)₂B(OR₅)₂; wherein each R₄ is independently H, OH, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl.


[00132] In some embodiments is a compound of Formula (I), (II), or (IIa) wherein A is a carboxylic acid isostere selected from -SO₃H, -SO₂NHR₄, -P(O)(OR₄)₂, -P(O)(R₄)(OR₄), -C(O)R₄, -CON(R₄)₂, -CONHNHSO₂R₄, -CONHSO₂R₄, -B(OR₅)₂, -C(R₄)₂B(OR₅)₂, and -CON(R₄)C(R₄)₂B(OR₅)₂; wherein each R₄ is independently H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl.

[00133] In further embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁. In yet further embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. In some embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is H. In some embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is substituted or unsubstituted alkyl. In some embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is CH₃. In yet further embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is substituted or unsubstituted heteroalkyl. In other embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is substituted or unsubstituted heterocycloalkyl. In some embodiments is a compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is substituted or unsubstituted aryl. In other embodiments is a

compound of Formula (I), (II), or (IIa) wherein X is CR₁; and R₁ is substituted or unsubstituted heteroaryl.

[00134] In some embodiments is a compound of Formula (I), (II), or (IIa) wherein X is N.

[00135] In another aspect are compounds having the structure of Formula (III):



Formula (III);


wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00136] In another aspect are compounds having the structure of Formula (IV):



Formula (IV);


wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00137] In another aspect are compounds having the structure of Formula (IVa):




Formula (IVa);

wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00138] In some embodiments is a compound of Formula (III), (IV), or (IVa) wherein A is a carboxylic acid isostere selected from:




[00139] In some embodiments is a compound of Formula (III), (IV), or (IVa) wherein A is a carboxylic acid isostere selected from -SO₃H, -SO₂NHR₄, -P(O)(OR₄)₂, -P(O)(R₄)(OR₄), -CON(R₄)₂, -CONHNHSO₂R₄, -CONHSO₂R₄, -B(OR₅)₂, -C(R₄)₂B(OR₅)₂, and -CON(R₄)C(R₄)₂B(OR₅)₂; wherein each R₄ is independently H, OH, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl.


[00140] In some embodiments is a compound of Formula (III), (IV), or (IVa) wherein A is a carboxylic acid isostere selected from -SO₃H, -SO₂NHR₄, -P(O)(OR₄)₂, -P(O)(R₄)(OR₄), -C(O)NR₄, -CON(R₄)₂, -CONHNHSO₂R₄, -CONHSO₂R₄, -B(OR₅)₂, -C(R₄)₂B(OR₅)₂, and -CON(R₄)C(R₄)₂B(OR₅)₂; wherein each R₄ is independently H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl.

[00141] In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein R_2 and R_3 are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein R_2 and R_3 are each H. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein R_2 and R_3 are each independently substituted or unsubstituted alkyl. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein R_2 and R_3 are each independently substituted or unsubstituted heteroalkyl.


[00142] In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa),




(III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a




compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is . In any of the aforementioned embodiments is a compound of Formula




(I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is




. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa),




(III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a



compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is . In any of the aforementioned embodiments is a compound of Formula




(I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned


embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is




. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa),




(III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a




compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the
aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is . In any of the aforementioned embodiments is a compound of Formula




(I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned
embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is




. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa),




(III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a




compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the
aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is . In any of the aforementioned embodiments is a compound of Formula




(I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned
embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is




. In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa),




(III), (IV), or (IVa) wherein A is HO- . In any of the aforementioned embodiments is a




compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is . In any of the aforementioned embodiments is a compound of




Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)



wherein A is . In any of the aforementioned embodiments is a compound of




Formula (I), (II), (IIa), (III), (IV), or (IVa) wherein A is . In any of the aforementioned embodiments is a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa)




wherein A is .


[00143] In one embodiment is a compound having the structure:




[00144] In one embodiment is a compound having the structure:





[00145] In one embodiment is a compound having the structure:





[00146] In some embodiments is a compound selected from:












; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00147] In some embodiments is a compound selected from:



; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[00148] Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, wherein the compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is as described herein.

Routes of Administration

[00149] Suitable routes of administration include, but are not limited to, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and/or intranasal injections.

[00150] In certain embodiments, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is administered in a local rather than systemic manner, for example, via topical application of the compound directly on to skin, or intravenously, or subcutaneously, often in a depot preparation or sustained release formulation. In specific embodiments, long acting formulations are

administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically (e.g., as a patch, an ointment, or in combination with a wound dressing, or as a wash or a spray). In alternative embodiments, a formulation is administered systemically (e.g., by injection, or as a pill).

Pharmaceutical Compositions/Formulations

[00151] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.

[00152] Provided herein are pharmaceutical compositions that include a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) and at least one pharmaceutically acceptable inactive ingredient. In some embodiments, the compounds described herein are administered as pharmaceutical compositions in which compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) are mixed with other active ingredients, as in combination therapy. In other embodiments, the pharmaceutical compositions include other medicinal or pharmaceutical agents, carriers, adjuvants, preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers. In yet other embodiments, the pharmaceutical compositions include other therapeutically valuable substances.

[00153] A pharmaceutical composition, as used herein, refers to a mixture of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism. In practicing the methods of treatment or use

provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.


[00154] The pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[00155] Pharmaceutical compositions including a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[00156] The pharmaceutical compositions will include at least one compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use of *N*-oxides (if appropriate), crystalline forms, amorphous phases, as well as active metabolites of these compounds having the same type of activity. In some embodiments, compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) exist in unsolvated form or in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) are also considered to be disclosed herein.

[00157] In some embodiments, the compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) exist as tautomers. All tautomers are included within the scope of the compounds presented herein. As such, it is to be understood that a compound of the Formula (I), (II), (IIa), (III), (IV), or (IVa) or a salt thereof may exhibit the phenomenon of tautomerism whereby two chemical compounds that are capable of facile interconversion by exchanging a hydrogen atom between two atoms, to either of which it forms a covalent bond. Since the tautomeric compounds exist in mobile equilibrium with each other they may be regarded as different isomeric forms of the

same compound. It is to be understood that the formulae drawings within this specification can represent only one of the possible tautomeric forms. However, it is also to be understood that the present disclosure encompasses any tautomeric form, and is not to be limited merely to any one tautomeric form utilized within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been convenient to show graphically herein. For example, tautomerism may be exhibited by a tetrazole group or a triazole group bonded as indicated by the wavy line:



[00158] In some embodiments, compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) exist as enantiomers, diastereomers, or other stereoisomeric forms. The compounds disclosed herein include all enantiomeric, diastereomeric, and epimeric forms as well as mixtures thereof.

[00159] In some embodiments, compounds described herein may be prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.

[00160] Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a compound of (I), (II), (IIa), (III), (IV), or (IVa) as set forth herein are

included within the scope of the claims. Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) as set forth herein are included within the scope of the claims. In some cases, some of the compounds described herein may be a prodrug for another derivative or active compound. In some embodiments described herein, hydrazones are metabolized in vivo to produce a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa).

[00161] In certain embodiments, compositions provided herein include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[00162] In some embodiments, formulations described herein benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

[00163] The pharmaceutical compositions described herein, which include a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.

Certain topical compositions

[00164] In some embodiments, compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) are prepared as transdermal dosage forms. In one embodiment, the transdermal formulations described herein include at least three components: (1) a formulation of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa); (2) a penetration enhancer; and (3) an optional aqueous adjuvant. In some embodiments the transdermal formulations include additional components such as, but not limited to, gelling agents, creams and ointment bases, and the like. In some embodiments, the transdermal formulation is presented as a patch or a wound dressing. In some embodiments, the transdermal formulation further include a woven or non-woven backing

material to enhance absorption and prevent the removal of the transdermal formulation from the skin. In other embodiments, the transdermal formulations described herein can maintain a saturated or supersaturated state to promote diffusion into the skin.

[00165] In one aspect, formulations suitable for transdermal administration of compounds described herein employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. In one aspect, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Still further, transdermal delivery of the compounds described herein can be accomplished by means of iontophoretic patches and the like. In one aspect, transdermal patches provide controlled delivery of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa). In one aspect, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

[00166] In further embodiments, topical formulations include gel formulations (e.g., gel patches which adhere to the skin). In some of such embodiments, a gel composition includes any polymer that forms a gel upon contact with the body (e.g., gel formulations comprising hyaluronic acid, pluronic polymers, poly(lactic-co-glycolic acid (PLGA)-based polymers or the like). In some forms of the compositions, the formulation comprises a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter which is first melted. Optionally, the formulations further comprise a moisturizing agent.

[00167] In certain embodiments, delivery systems for pharmaceutical compounds may be employed, such as, for example, liposomes and emulsions. In certain embodiments, compositions provided herein can also include an mucoadhesive polymer, selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.

[00168] In some embodiments, the compounds described herein may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[00169] In alternative embodiments, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is formulated and presented as a wash or rinse liquid which is used to irrigate the affected area. In further embodiments, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is formulated and presented as a spray which is applied to the affected area.

Wound dressings

[00170] In one aspect, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is presented as part of a wound dressing. A dressing is an adjunct used for application to a wound to promote healing and/or prevent further harm. A dressing is designed to be in direct contact with a wound. In some embodiments, a wound dressing comprising a CSE inhibitor described herein provides a controlled release of the CSE inhibitor. In other embodiments, a wound dressing comprising a CSE inhibitor described herein provides sustained release of the CSE inhibitor. In other embodiments, a wound dressing comprising a CSE inhibitor described herein provides intermediate release of the CSE inhibitor. In further embodiments, a wound dressing comprising a CSE inhibitor described herein provides intermediate release of the CSE inhibitor. In other embodiments, a wound dressing comprising a CSE inhibitor described herein provides a combination of sustained, intermediate or immediate release of the CSE inhibitor.

[00171] Optionally a wound dressing comprising a CSE inhibitor comprises particles of the CSE inhibitor designed for controlled release (e.g., micronized particles, nanosized particles or a mixture thereof, non-sized particles, coated particles for controlled and/or sustained release). In some embodiments, a wound dressing is a gel patch that adheres to the skin at the site of the wound or cutaneous injury or condition. In some embodiments, a gel patch comprises any suitable gelling polymer (e.g., hyaluronan, carbomer polymers, pluronic polymers, PLGA polymers or the like). In some embodiments, a wound dressing comprises a coating on a sticky tape (e.g., medicated bandage or tape). In some embodiments, a wound dressing is a liquid which gels upon contacting the skin and is administered as a spray-on or paint.

[00172] In some additional embodiments, a CSE inhibitor is administered topically or systemically in combination with a wound dressing. In some of such embodiments, the wound dressing is non-medicated (i.e., does not comprise the CSE inhibitor). In some other embodiments, the wound dressing comprises a CSE inhibitor as described above.

[00173] In further embodiments, a CSE inhibitor is administered topically or systemically in combination with a wound dressing and a bandage.

Certain systemically administered compositions

[00174] In one aspect, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection. In one aspect, formulations suitable for intramuscular, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive

oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In some embodiments, formulations suitable for subcutaneous injection also contain additives such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. In some cases it is desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

[00175] For intravenous injections or drips or infusions, compounds described herein are formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients. Such excipients are known.

[00176] Parenteral injections may involve bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In one aspect, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[00177] For administration by inhalation, a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is formulated for use as an aerosol, a mist or a powder. Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.

[00178] Representative intranasal formulations are described in, for example, U.S. Pat. Nos. 4,476,116, 5,116,817 and 6,391,452. Formulations that include a compound of Formula (I) are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives,

fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. *et al.*, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Sixth Ed. (1995). Preferably these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients. These ingredients are known to those skilled in the preparation of nasal dosage forms and some of these can be found in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21st edition, 2005. The choice of suitable carriers is dependent upon the exact nature of the nasal dosage form desired, e.g., solutions, suspensions, ointments, or gels. Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present. Preferably, the nasal dosage form should be isotonic with nasal secretions.

[00179] Pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. In some embodiments, dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[00180] In some embodiments, pharmaceutical formulations of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) are in the form of a capsules, including push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added. A capsule may be prepared, for example, by placing the bulk blend of the formulation of the compound described above, inside of a capsule. In some embodiments, the formulations (non-aqueous suspensions and solutions) are placed in a soft gelatin capsule. In other embodiments, the formulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC. In other embodiments, the

formulation is placed in a sprinkle capsule, wherein the capsule is swallowed whole or the capsule is opened and the contents sprinkled on food prior to eating.

[00181] All formulations for oral administration are in dosages suitable for such administration.

[00182] In one aspect, solid oral dosage forms are prepared by mixing a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) with one or more of the following: antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.

[00183] In some embodiments, the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder, a capsule, solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, beads, pellets, granules. In other embodiments, the pharmaceutical formulation is in the form of a powder.

[00184] Compressed tablets are solid dosage forms prepared by compacting the bulk blend of the formulations described above. In various embodiments, tablets will include one or more flavoring agents.

[00185] In other embodiments, the tablets will include a film surrounding the final compressed tablet. In some embodiments, the film coating can provide a delayed release of the compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) from the formulation. In other embodiments, the film coating aids in patient compliance (e.g., Opadry® coatings or sugar coating). Film coatings including Opadry® typically range from about 1% to about 3% of the tablet weight.

[00186] In some embodiments, solid dosage forms, e.g., tablets, effervescent tablets, and capsules, are prepared by mixing particles of a compound with one or more pharmaceutical excipients to form a bulk blend composition. The bulk blend is readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. In some embodiments, the individual unit dosages include film coatings. These formulations are manufactured by conventional formulation techniques.

[00187] In another aspect, dosage forms include microencapsulated formulations. In some embodiments, one or more other compatible materials are present in the microencapsulation material. Exemplary materials include, but are not limited to, pH modifiers, erosion facilitators, anti-foaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.

[00188] Exemplary useful microencapsulation materials include, but are not limited to, hydroxypropyl cellulose ethers (HPC) such as Klucel® or Nisso HPC, low-substituted hydroxypropyl cellulose ethers (L-HPC), hydroxypropyl methyl cellulose ethers (HPMC) such

as Seppifilm-LC, Pharmacoat®, Metolose SR, Methocel®-E, Opadry YS, PrimaFlo, Benecel MP824, and Benecel MP843, methylcellulose polymers such as Methocel®-A, hydroxypropylmethylcellulose acetate stearate Aqoat (HF-LS, HF-LG, HF-MS) and Metolose®, Ethylcelluloses (EC) and mixtures thereof such as E461, Ethocel®, Aqualon®-EC, Surelease®, Polyvinyl alcohol (PVA) such as Opadry AMB, hydroxyethylcelluloses such as Natrosol®, carboxymethylcelluloses and salts of carboxymethylcelluloses (CMC) such as Aqualon®-CMC, polyvinyl alcohol and polyethylene glycol co-polymers such as Kollicoat IR®, monoglycerides (Myverol), triglycerides (KLX), polyethylene glycols, modified food starch, acrylic polymers and mixtures of acrylic polymers with cellulose ethers such as Eudragit® EPO, Eudragit® L30D-55, Eudragit® FS 30D Eudragit® L100-55, Eudragit® L100, Eudragit® S100, Eudragit® RD100, Eudragit® E100, Eudragit® L12.5, Eudragit® S12.5, Eudragit® NE30D, and Eudragit® NE 40D, cellulose acetate phthalate, sepiifilms such as mixtures of HPMC and stearic acid, cyclodextrins, and mixtures of these materials.

[00189] Liquid formulation dosage forms for oral administration are optionally aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to a CSE inhibitor, the liquid dosage forms optionally include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions further includes a crystal-forming inhibitor.

[00190] In some embodiments, the pharmaceutical formulations described herein are self-emulsifying drug delivery systems (SEDDES). Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets. Generally, emulsions are created by vigorous mechanical dispersion. SEDDES, as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation. An advantage of SEDDES is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase is optionally added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient. Thus, the SEDDES provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients. In some embodiments, SEDDES provides improvements in the bioavailability of hydrophobic active ingredients. Methods of producing self-emulsifying dosage forms include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563.

[00191] Buccal formulations that include a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered using a variety of formulations known in the art. For example, such

formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein can further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.

[00192] For intravenous injections, a CSE inhibitor is optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. For other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.

[00193] Parenteral injections optionally involve bolus injection or continuous infusion. Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative. In some embodiments, a pharmaceutical composition described herein is in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of an agent that modulates the activity of a carotid body in water soluble form. Additionally, suspensions of an agent that modulates the activity of a carotid body are optionally prepared as appropriate, e.g., oily injection suspensions.

[00194] Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.

[00195] Suitable carriers for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose, microcrystalline cellulose, lactose, mannitol and the like.

[00196] Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrans, dextrans, starches, pregelatinized starch, hydroxypropylmethylcellulose (HPMC),

hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.

[00197] Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, natural starch such as corn starch or potato starch, a pregelatinized starch, or sodium starch glycolate, a cellulose such as methylcrystalline cellulose, methylcellulose, microcrystalline cellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a cross-linked polymer such as crospovidone, a cross-linked polyvinylpyrrolidone, alginate such as alginic acid or a salt of alginic acid such as sodium alginate, a gum such as agar, guar, locust bean, Karaya, pectin, or tragacanth, sodium starch glycolate, bentonite, sodium lauryl sulfate, sodium lauryl sulfate in combination starch, and the like.

[00198] Binders impart cohesiveness to solid oral dosage form formulations: for powder filled capsule formulation, they aid in plug formation that can be filled into soft or hard shell capsules and for tablet formulation, they ensure the tablet remaining intact after compression and help assure blend uniformity prior to a compression or fill step. Materials suitable for use as binders in the solid dosage forms described herein include, but are not limited to, carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose, microcrystalline dextrose, amylose, magnesium aluminum silicate, polysaccharide acids, bentonites, gelatin, polyvinylpyrrolidone/vinyl acetate copolymer, crospovidone, povidone, starch, pregelatinized starch, tragacanth, dextrin, a sugar, such as sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, lactose, a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, starch, polyvinylpyrrolidone, larch arabogalactan, polyethylene glycol, waxes, sodium alginate, and the like.

[00199] In general, binder levels of 20-70% are used in powder-filled gelatin capsule formulations. Binder usage level in tablet formulations varies whether direct compression, wet granulation, roller compaction, or usage of other excipients such as fillers which itself can act as moderate binder. Binder levels of up to 70% in tablet formulations is common.

[00200] Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, Stearowet[®], boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a

methoxypolyethylene glycol such as Carbowax™, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like.

[00201] Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrans and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins and the like.

[00202] Suitable wetting agents for use in the solid dosage forms described herein include, for example, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, quaternary ammonium compounds (e.g., Polyquat 10®), sodium oleate, sodium lauryl sulfate, magnesium stearate, sodium docusate, triacetin, vitamin E TPGS and the like.

[00203] Suitable surfactants for use in the solid dosage forms described herein include, for example, sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), and the like.

[00204] Suitable suspending agents for use in the solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, vinyl pyrrolidone/vinyl acetate copolymer (S630), sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, celluloses, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like.

[00205] Suitable antioxidants for use in the solid dosage forms described herein include, for example, e.g., butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.

[00206] It should be appreciated that there is considerable overlap between additives used in the solid dosage forms described herein. Thus, the above-listed additives should be taken as merely exemplary, and not limiting, of the types of additives that can be included in solid dosage forms of the pharmaceutical compositions described herein. The amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired.

[00207] In various embodiments, the particles of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) and one or more excipients are dry blended and compressed into a mass, such as a tablet, having a hardness sufficient to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes, after oral administration, thereby releasing the formulation into the gastrointestinal fluid.

[00208] In other embodiments, a powder including a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is formulated to include one or more pharmaceutical excipients and flavors. Such a powder is prepared, for example, by mixing the compound and optional pharmaceutical excipients to form a bulk blend composition. Additional embodiments also include a suspending agent and/or a wetting agent. This bulk blend is uniformly subdivided into unit dosage packaging or multi-dosage packaging units.

[00209] In still other embodiments, effervescent powders are also prepared. Effervescent salts have been used to disperse medicines in water for oral administration.

Controlled release formulations

[00210] In some embodiments, the pharmaceutical dosage forms are formulated to provide a controlled release of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa). Controlled release refers to the release of the compound from a dosage form in which it is incorporated according to a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile. Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.

[00211] In some embodiments, the solid dosage forms described herein are formulated as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which utilizes an enteric coating to affect release in the small intestine or large intestine. In one aspect, the enteric coated dosage form is a compressed or molded or extruded tablet/mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and/or other composition components, which are themselves coated or uncoated. In one aspect, the enteric coated oral dosage form is in the form of a capsule

containing pellets, beads or granules, which include a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa), that are coated or uncoated.

[00212] Any coatings should be applied to a sufficient thickness such that the entire coating does not dissolve in the gastrointestinal fluids at pH below about 5, but does dissolve at pH about 5 and above. Coatings are typically selected from any of the following:

[00213] Shellac - this coating dissolves in media of pH >7; Acrylic polymers - examples of suitable acrylic polymers include methacrylic acid copolymers and ammonium methacrylate copolymers. The Eudragit series E, L, S, RL, RS and NE (Rohm Pharma) are available as solubilized in organic solvent, aqueous dispersion, or dry powders. The Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for colonic targeting. The Eudragit series E dissolve in the stomach. The Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine; Poly Vinyl Acetate Phthalate (PVAP) - PVAP dissolves in pH >5, and it is much less permeable to water vapor and gastric fluids.

[00214] Conventional coating techniques such as spray or pan coating are employed to apply coatings. The coating thickness must be sufficient to ensure that the oral dosage form remains intact until the desired site of topical delivery in the intestinal tract is reached.

[00215] In other embodiments, the formulations described herein are delivered using a pulsatile dosage form. A pulsatile dosage form is capable of providing one or more immediate release pulses at predetermined time points after a controlled lag time or at specific sites. Exemplary pulsatile dosage forms and methods of their manufacture are disclosed in U.S. Pat. Nos. 5,011,692, 5,017,381, 5,229,135, 5,840,329 and 5,837,284. In one embodiment, the pulsatile dosage form includes at least two groups of particles, (i.e. multiparticulate) each containing the formulation described herein. The first group of particles provides a substantially immediate dose of the compound of Formula (I) upon ingestion by a mammal. The first group of particles can be either uncoated or include a coating and/or sealant. In one aspect, the second group of particles comprises coated particles. The coating on the second group of particles provides a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose. Suitable coatings for pharmaceutical compositions are described herein or known in the art.

[00216] In some embodiments, pharmaceutical formulations are provided that include particles of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) and at least one dispersing agent or suspending agent for oral administration to a subject. The formulations may be a powder and/or granules for suspension, and upon admixture with water, a substantially uniform suspension is obtained.

[00217] In some embodiments, particles formulated for controlled release are incorporated in a gel or a patch or a wound dressing.

[00218] In one aspect, liquid formulation dosage forms for oral administration and/or for topical administration as a wash are in the form of aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh *et al.*, Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to the particles of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa), the liquid dosage forms include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions can further include a crystalline inhibitor.

[00219] In some embodiments, the liquid formulations also include inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, sodium lauryl sulfate, sodium doccuate, cholesterol, cholesterol esters, taurocholic acid, phosphatidylcholine, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.

[00220] Furthermore, pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

[00221] Additionally, pharmaceutical compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

[00222] Other pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[00223] In one embodiment, the aqueous suspensions and dispersions described herein remain in a homogenous state, as defined in The USP Pharmacists' Pharmacopeia (2005 edition, chapter 905), for at least 4 hours. In one embodiment, an aqueous suspension is re-suspended into a homogenous suspension by physical agitation lasting less than 1 minute. In still another embodiment, no agitation is necessary to maintain a homogeneous aqueous dispersion.

[00224] Examples of disintegrating agents for use in the aqueous suspensions and dispersions include, but are not limited to, a starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch, or sodium starch glycolate; a cellulose such as methylcrystalline cellulose, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose; a cross-linked starch such as sodium starch glycolate; a cross-linked polymer such as crospovidone; a cross-linked polyvinylpyrrolidone; alginate such as alginic acid or a salt of alginic acid such as sodium alginate; a gum such as agar, guar, locust bean, Karaya, pectin, or tragacanth; sodium starch glycolate; bentonite; a natural sponge; a surfactant; a resin such as a cation-exchange resin; citrus pulp; sodium lauryl sulfate; sodium lauryl sulfate in combination starch; and the like.

[00225] In some embodiments, the dispersing agents suitable for the aqueous suspensions and dispersions described herein include, for example, hydrophilic polymers, electrolytes, Tween[®] 60 or 80, PEG, polyvinylpyrrolidone, and the carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropyl cellulose ethers, hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, hydroxypropylmethyl-cellulose acetate stearate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone/vinyl acetate copolymer, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers; and poloxamines. In other embodiments, the dispersing agent is selected from a group not comprising one of the following agents: hydrophilic polymers; electrolytes; Tween[®] 60 or 80; PEG; polyvinylpyrrolidone (PVP); hydroxypropylcellulose and hydroxypropyl cellulose ethers; hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers; carboxymethylcellulose sodium; methylcellulose; hydroxyethylcellulose; hydroxypropylmethyl-cellulose phthalate; hydroxypropylmethyl-cellulose acetate stearate; non-crystalline cellulose; magnesium aluminum silicate; triethanolamine; polyvinyl alcohol (PVA); 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde; poloxamers; or poloxamines.

[00226] Wetting agents suitable for the aqueous suspensions and dispersions described herein include, but are not limited to, cetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan

fatty acid esters (e.g., the commercially available Tweens[®] such as e.g., Tween 20[®] and Tween 80[®], and polyethylene glycols, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium taurocholate, simethicone, phosphatidylcholine and the like

[00227] Suitable preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben), benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride. Preservatives, as used herein, are incorporated into the dosage form at a concentration sufficient to inhibit microbial growth.

[00228] Suitable viscosity enhancing agents for the aqueous suspensions or dispersions described herein include, but are not limited to, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, Plasdon[®] S-630, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof. The concentration of the viscosity enhancing agent will depend upon the agent selected and the viscosity desired.

[00229] Examples of sweetening agents suitable for the aqueous suspensions or dispersions described herein include, for example, acacia syrup, acesulfame K, alitame, aspartame, chocolate, cinnamon, citrus, cocoa, cyclamate, dextrose, fructose, ginger, glycyrrhetate, glycyrrhiza (licorice) syrup, monoammonium glycyrrhizinate (MagnaSweet[®]), maltol, mannitol, menthol, neohesperidine DC, neotame, Prosweet[®] Powder, saccharin, sorbitol, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, acesulfame potassium, mannitol, sucralose, tagatose, thaumatin, vanilla, xylitol, or any combination thereof.

Methods of Dosing and Treatment Regimens

[00230] A method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions that include at least one compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said subject. In another embodiment, the compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) are used in the preparation of medicaments for the treatment of acute kidney injury (AKI) secondary to a toxic agent (e.g., cisplatin, aminoglycosides, and radiologic contrast material), nociceptive pain, acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, mixed neuropathic pain and inflammatory pain states, rheumatoid arthritis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, acute pancreatitis, chronic pancreatitis, pain associated with acute pancreatitis,

pain associated with chronic pancreatitis, migraine headache, gout, ankylosing spondylitis, systemic lupus erythematosus (SLE), system inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), asthma, chronic obstructive pulmonary disease (COPD), sensitive skin, acne, rosacea, contact dermatitis, or pain associated with cancer, or conditions as described herein. In another embodiment, the compounds of Formula (I), (II), (IIa), (III), (IV), or (IVa) are used in the preparation of medicaments for the treatment of acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, rheumatoid arthritis, osteoarthritis, or migraine headache.

[00231] In certain embodiments, the compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation clinical trial.

[00232] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount or dose." In this use, the precise amounts also depend on the patient's state of health, weight, and the like. When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. In one aspect, prophylactic treatments include administering to a mammal, who previously experienced at least one symptom of the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) in order to prevent a return of the symptoms of the disease or condition.

[00233] In certain embodiments wherein the patient's condition does not improve, upon the doctor's discretion the administration of the compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) is administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.

[00234] In certain embodiments wherein a patient's status does improve, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (*i.e.*, a "drug holiday"). In specific embodiments, the length of the drug holiday is between 2

days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug holiday is, by way of example only, by 10%-100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

[00235] In certain embodiments the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (*i.e.*, a “drug diversion”). In specific embodiments, the length of the drug diversion is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug diversion is, by way of example only, by 10%-100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%. After a suitable length of time, the normal dosing schedule is optionally reinstated.

[00236] In some embodiments, once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms.

[00237] The amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (*e.g.*, weight, sex) of the subject or host in need of treatment, but can nevertheless be determined according to the particular circumstances surrounding the case, including, *e.g.*, the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. In general, however, doses employed for adult human treatment are typically in the range of 0.01mg-5000 mg per day. In one aspect, doses employed for adult human treatment are from about 1mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.

[00238] In some embodiments, as a patient is started on a regimen of a CSE inhibitor, the patient is also weaned off (*e.g.*, step-wise decrease in dose) a second treatment regimen (*e.g.*, a methylxanthine).

[00239] In one embodiment, the daily dosages appropriate for a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) described herein are from about 0.01 to about 10 mg/kg per body weight. In specific embodiments, an indicated daily dosage in a large mammal, including, but

not limited to, humans, is in the range from about 0.5 mg to about 1000 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day. In one embodiment, the daily dosage is administered in extended release form. In certain embodiments, suitable unit dosage forms for oral administration comprise from about 1 to 500 mg active ingredient. In other embodiments, the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.

[00240] Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD₅₀ and the ED₅₀. The dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD₅₀ and ED₅₀. In certain embodiments, the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans. In some embodiments, the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED₅₀ with minimal toxicity. In certain embodiments, the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.

Combination therapy

[00241] In one embodiment, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with an anti-inflammatory agent. Examples of such anti-inflammatory agents include and are not limited to analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, and the like.

[00242] In another embodiment, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with a pain medication. Examples of such pain medications include and are not limited to paracetamol, gabapentin, pregablin, duloxetine, the non-steroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, opioid drugs such as morphine and opium, and analogues such as codeine, oxycodone and the like, as well as opioid-sparing compounds.

[00243] In additional embodiments, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with an antiseptic agent (e.g., hydrogen peroxide, iodine, chlorhexidine, boric acid, benzalkonium chloride (BAC), cetyl

trimethylammonium bromide (CTMB), cetylpyridinium chloride (Cetrim, CPC), benzethonium chloride (BZT) and the like.

[00244] In further embodiments, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with an anesthetic agent (e.g., benzocaine, lidocaine and the like).

[00245] In additional embodiments, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with one or more agents used to treat allergy, including, but not limited to: antihistamine and decongestant combinations (cetirizine and pseudoephedrine; desloratadine and pseudoephedrine ER; fexofenadine and pseudoephedrine; loratadine and pseudoephedrine); antihistamines (azelastine nasal spray; brompheniramine; brompheniramine oral suspension; carbinoxamine; cetirizine; chlorpheniramine; clemastine; desloratadine; dexchlorpheniramine ER; dexchlorpheniramine oral syrup; diphenhydramine oral; fexofenadine; loratadine; promethazine); decongestants (pseudoephedrine); leukotriene modifiers (montelukast; montelukast granules); nasal anticholinergics (ipratropium); nasal corticosteroids (beclomethasone nasal inhalation; budesonide nasal inhaler; flunisolide nasal inhalation; fluticasone nasal inhalation; mometasone nasal spray; triamcinolone nasal inhalation; triamcinolone nasal spray); nasal decongestants (phenylephrine); nasal mast cell stabilizers (cromolyn nasal spray) and the like.

[00246] In further embodiments, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with antibiotics. In yet other embodiments, the CSE inhibitors of Formula (I), (II), (IIa), (III), (IV), or (IVa) are administered to an individual in need thereof in combination with a wound dressing.

[00247] Examples of agents suitable for combination therapy with an agent that modulates the activity of the carotid body include carbonic anhydrase inhibitors (e.g., acetazolamide), cholinesterase inhibitors (e.g., donepezil), adenosine inhibitors (e.g., theophylline), progestational agents (e.g., progesterone), opioid antagonists (e.g., naloxone), central nervous system stimulants (e.g., nicotine), serotonergic agents (e.g., paroxetine) including selective serotonin reuptake inhibitors (SSRIs), antidepressants (e.g., protriptyline) including conventional and/or tricyclic antidepressants, antihypertensives (e.g., metoprolol, cilazapril, propranolol, atenolol, hydrochlorothiazide), calcium channel antagonists (e.g., isradipine), ACE inhibitors (e.g., spirapril), respiratory stimulants (e.g., doxapram), alpha-2 adrenergic agonists (e.g., clonidine), gamma aminobutyric acid agonists (e.g., baclofen), glutamate antagonists (e.g., sabeluzole), or gaseous respiration stimulants such as carbon dioxide.

Combination Formulations and Kits

[00248] Also provided herein are kits for therapies described herein. In some embodiments, the kit comprises a CSE inhibitor and a second treatment regimen. Such kits generally will comprise one or more of the active agent as disclosed herein, and instructions for using the kit.

[00249] In some embodiments, kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) including one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. In other embodiments, the containers are formed from a variety of materials such as glass or plastic.

[00250] In certain embodiments, the pharmaceutical compositions are presented in a pack or dispenser device which contains one or more unit dosage forms containing a CSE inhibitor. In another embodiment, the pack for example contains metal or plastic foil, such as a blister pack.

Assays for identification of CSE inhibitors

[00251] In some embodiments, CSE inhibitors are identified by use of in vitro assays. By way of example, an in vitro assay for CSE enzyme activity is described in Zhong et al. *Chinese Medical Journal*, 2009, 122, 326-330. In some embodiments, in vitro enzyme assays are adapted for high-throughput screening (HTS) using any suitable method.

[00252] In some embodiments, in vivo assays are used to determine the effect of CSE inhibitor. In some embodiments, an in vivo assay for identifying a CSE inhibitor comprises

(a) preparing organ or tissue homogenates from a test animal that has been administered a test compound; and

(b) calculating H₂S concentration based on absorbance;

wherein a decrease in H₂S concentration indicates that the test compound is a CSE inhibitor. In some embodiments of the aforementioned assay, the test animal is subjected to normoxia, acute hypoxia, chronic intermittent hypoxia, hypercapnia, or a combination thereof. Optional intermediate steps include:

effecting enzymatic reaction on L-cysteine;

quenching the enzymatic reaction with zinc acetate and trichloroacetic acid;

reacting the zinc sulfide with acidic N,N-dimethyl-p-phenyldiamine sulfate and ferric chloride; and

measuring the absorbance of the assay mixture with a micro-plate reader.

[00253] In some embodiments, an in vivo assay for identifying a CSE inhibitor comprises

(a) isolating an organ or tissue from a test animal that has been administered a test compound;

(b) challenging the organ or tissue in the recording chamber by perfusing the recording chamber with varying levels of oxygen and/or carbon dioxide; and

(c) recording action potentials;

wherein a decrease in action potential indicates that the test compound is a CSE inhibitor. In some embodiments of the aforementioned assay, the test animal is subjected to normoxia, acute hypoxia, chronic intermittent hypoxia, hypercapnia, or a combination thereof. Optional intermediate steps include:

placing the organ or tissue in a recording chamber superfused with warm physiological saline.


[00254] Optional instruments for recording action potentials include a suction electrode on a PowerLab/8P machine.

EXAMPLES

[00255] The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[00256] All synthetic chemistry was performed in standard laboratory glassware unless indicated otherwise in the examples. Commercial reagents were used as received.

Example 1: Synthesis of 3-amino-3-(1H-tetrazol-5-yl)propionitrile dihydrochloride (7)



Step 1: Synthesis of 3-tert-butoxycarbonylamino-succinamic acid benzyl ester (2)

[00257] To a solution of 4-(benzyloxy)-2-(tert-butoxycarbonylamino)-4-oxobutanoic acid (1) (4.68 g, 14.46 mmol) and triethylamine (2.42 mL) in anhydrous tetrahydrofuran (73 mL) was added ethyl chloroformate (1.66 mL, 17.36 mmol) at 0 °C. After 0.5 h, 25 % aqueous ammonia (23.2 mL) was added, and the reaction was stirred for 1 h. The reaction mixture was evaporated and the residue was triturated with water (70 mL) to afford 3-tert-butoxycarbonylamino-succinamic acid benzyl ester (2) (3.30 g, 10.26 mmol, 71%) as a white crystalline solid. ESMS m/z 345 ($M+Na$)⁺.

Step 2: Synthesis of 3-*tert*-butoxycarbonylamino-3-cyanopropionic acid benzyl ester (3)

[00258] To a mixture of 3-*tert*-butoxycarbonylamino-succinamic acid benzyl ester (2) (3.30 g, 10.26 mmol) and pyridine (4.30 mL) in 1,4-dioxane (46 mL) was added trifluoroacetic acid anhydride (2.98 mL, 21.42 mmol) at 0 °C. The resulting reaction mixture was stirred for 10 min at 0 °C, then warmed to 15 °C and stirred for 30 min. A 10% solution of sodium bicarbonate (50 mL) was added dropwise, the mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was triturated with *n*-hexane (30 mL) to give 3-*tert*-butoxycarbonylamino-3-cyanopropionic acid benzyl ester (3) (2.94 g, 9.66 mmol, 94%) as a pale yellow crystalline solid. ESMS m/z 327 (M+Na)⁺.

Step 3: Synthesis of 3-*tert*-butoxycarbonylamino-3-(1*H*-tetrazol-5-yl)propionic acid benzyl ester (4)

[00259] A mixture of 3-*tert*-butoxycarbonylamino-3-cyanopropionic acid benzyl ester (3) (1.00 g, 3.28 mmol), ammonium chloride (0.25 g, 4.67 mmol) and sodium azide (0.30 g, 4.61 mmol) in *N,N*-dimethylformamide (20 mL) was stirred at 110 °C for 3 h under nitrogen. The resulting solid was removed by filtration and washed with ethyl acetate (2 x 5 mL). The filtrate was evaporated and the residue taken up in a mixture of ethyl acetate (20 mL), water (5 mL) and 10% acetic acid (5 mL). The layers were separated and the organic layer dried over sodium sulfate, filtered and evaporated. The crude product was triturated with diisopropyl ether to give 3-*tert*-butoxycarbonylamino-3-(1*H*-tetrazol-5-yl)propionic acid benzyl ester (4) (0.55 g, 1.58 mmol, 48%) as an off-white crystalline solid. ESMS m/z 348 (M+H)⁺.

Step 4: Synthesis of [2-carbamoyl-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (5)

[00260] A mixture of 3-*tert*-butoxycarbonylamino-3-(1*H*-tetrazol-5-yl)propionic acid benzyl ester (4) (0.40 g, 1.15 mmol) and 40% ammonia in methanol (12 mL) was stirred at 70 °C for seven days. The reaction mixture was evaporated and the residue triturated with 2-propanol to give [2-carbamoyl-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (5) (0.14 g, 0.54 mmol, 48%) as an off-white crystalline solid. ESMS m/z 257 (M+H)⁺.

Step 5: Synthesis of [2-cyano-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (6)


[00261] To a mixture of [2-carbamoyl-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (85 mg, 0.33 mmol) (5) and pyridine (134 μ L, 1.66 mmol) in anhydrous 1,4-dioxane (18 mL) was added a solution of trifluoroacetic acid anhydride (94 μ L, 0.66 mmol) in anhydrous 1,4-dioxane (3 mL) at 10 °C. The resulting reaction mixture was stirred for 30 min. A 10% sodium bicarbonate solution was then added dropwise to achieve pH 7. The mixture was diluted with water (10 mL) and washed with dichloromethane (3 x 20 mL). The aqueous layer was evaporated and the residue suspended in ethanol. The precipitate was removed by filtration and

the filtrate was evaporated. The crude product was purified by column chromatography eluting with ethyl acetate:methanol (4:1), and the resulting residue triturated with diethyl ether to give [2-cyano-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (**6**) (77 mg, 0.32 mmol, 97%) as a white solid. ESMS *m/z* 239 (*M*+*H*)⁺.

Step 6: Synthesis of 3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (7**)**


[00262] A mixture of [2-cyano-1-(1*H*-tetrazol-5-yl)ethyl]carbamic acid *tert*-butyl ester (**6**) (48 mg, 0.20 mmol) and 3.8 M hydrogen chloride in 1,4-dioxane (1 mL) was stirred for 1 h. The reaction mixture was evaporated and the residue triturated with diethyl ether to give 3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (**7**) (22 mg, 0.10 mmol, 51%) as a white hygroscopic solid. ESMS *m/z* 137 (*M*-*H*)⁻; ¹H NMR (500 MHz, DMSO-*d*₆, salt) δ 9.05 (br. s, 3H), 5.19 (dd, *J* = 7.8, 5.4 Hz, 1H), 3.46 - 3.52 (m, 1H), 3.39 - 3.45 (m, 1H).

Example 1a: Synthesis of (S)-3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (7a**)**




[00263] Using the procedure of Example 1, but starting with (S)-4-(benzyloxy)-2-(*tert*-butoxycarbonylamino)-4-oxobutanoic acid, affords (S)-3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (**7a**).

Example 1b: Synthesis of (R)-3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (7b**)**



[00264] Using the procedure of Example 1, but starting with (R)-4-(benzyloxy)-2-(*tert*-butoxycarbonylamino)-4-oxobutanoic acid, affords (R)-3-amino-3-(1*H*-tetrazol-5-yl)propionitrile dihydrochloride (**7b**).

Example 2: Synthesis of (S)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (12**)**



Step 1: Synthesis of (S)-(1-carbamoyl-but-3-ynyl)-carbamic acid *tert*-butyl ester (9)

[00265] To a pre-cooled (0–5 °C) solution of (S)-2-*tert*-butoxycarbonylamino-pent-4-ynoic acid (**8**) (88.86 g, 0.417 mol) in dry tetrahydrofuran (1100 mL) under nitrogen was added *N*-methylmorpholine (49.0 mL, 44.59 g, 0.441 mol). Ethyl chloroformate (40.5 mL, 46.17 g, 0.425 mol) was added dropwise over 30 min, maintaining the temperature between 0–5 °C. The mixture was stirred for 30 min at 0 °C, then added dropwise over 30 min to a pre-cooled (0–5 °C) solution of aqueous ammonia (360 mL, 25 %) and stirred for 10 min. The aqueous layer was extracted with ethyl acetate (2 x 250 mL). The combined organic layers were washed with 10 % aqueous sodium carbonate (200 mL) and brine (100 mL), and evaporated to yield the crude product (80.50 g). The residue was triturated with water (80 mL) and the collected solid was washed with cold water (2 x 10 mL) to afford (S)-(1-carbamoyl-but-3-ynyl)-carbamic acid *tert*-butyl ester (**9**) (49.10 g, 0.231 mol, 55 %) as a white crystalline solid. LCMS (205 nm): 100%, (M+Na)⁺ 235; TLC in chloroform/acetic acid 20:1, visualized with chlorotoluidine: R_{fSM} = 0.45, R_{fprod} = 0.32.

Step 2: Synthesis of (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester (10)

[00266] (S)-(1-carbamoyl-but-3-ynyl)-carbamic acid *tert*-butyl ester (**9**) (48.04 g, 0.226 mol) was dissolved in a mixture of pyridine (94 mL, 92.30 g, 1.167 mol) and dry dioxane (940 mL) at 5 °C under nitrogen. Trifluoroacetic anhydride (66 mL, 98.14 g, 0.467 mol) was added dropwise, and the mixture was stirred for 30 min at 5 °C, then for 1 h at room temperature. The mixture was concentrated to *ca.* 250 mL *in vacuo*. The residue was added dropwise to saturated aqueous sodium bicarbonate (200 mL), maintaining the pH between 6 and 7 through the addition of solid sodium bicarbonate (99.40 g). Ethyl acetate (200 mL) was added, the inorganic solid was removed by filtration and the solid was extracted with ethyl acetate (100 mL). The combined filtrate was separated and the aqueous layer extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate and evaporated. The residue was triturated with hexane and the collected solid was washed with hexane (4 x 20 mL) to give (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester (**10**) (42.63 g, 0.219 mol, 97 %) as a tan solid. TLC in chloroform/acetic acid 20:1, visualized with chlorotoluidine: R_f = 0.67.


Step 3: Synthesis of (S)-[1-(1H-tetrazol-5-yl)-but-3-ynyl]-carbamic acid *tert*-butyl ester (11)

A mixture of (*S*)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester (**10**) (40.77 g, 0.212 mol), ammonium chloride (16.81 g, 0.314 mol) and sodium azide (20.42 g, 0.314 mol) in dry DMF (415 mL) was heated at 100 °C under nitrogen for 20 h. The inorganic solid was removed by filtration and the filtrate was evaporated. The residue was partitioned between ethyl acetate (500 mL) and 10 % aqueous sodium bicarbonate (250 mL). The aqueous layer was washed with ethyl acetate (2 x 100 mL), acidified to pH 4 with acetic acid, and extracted with ethyl acetate (2 x 100 mL). The combined acidic organic layers were washed with brine, dried over sodium sulfate, and evaporated. The crude product was triturated with hexane and the collected solid was washed with hexane (3 x 50 mL) to give (*S*)-[1-(1*H*-tetrazol-5-yl)-but-3-ynyl]-carbamic acid *tert*-butyl ester (**11**) (48.05 g, 0.202 mol, 96%) as an off-white crystalline solid. TLC in ethyl acetate/methanol 4:1, visualized with chlorotoluidine: $R_{f_{sm}} = 0.95$, $R_{f_{prod}} = 0.70$.

Step 4: Synthesis of (*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (12**)**


[00267] (*S*)-[1-(1*H*-tetrazol-5-yl)-but-3-ynyl]-carbamic acid *tert*-butyl ester (**11**) (43.26 g, 0.182 mol) was dissolved in 3.87 M hydrogen chloride in methanol (405 mL) and stirred at room temperature for 3 h. The mixture was evaporated and the residue was triturated with ethyl acetate (45 mL). The precipitate was washed with ethyl acetate (3 x 10 mL) to afford (*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (**12**) (27.20 g, 0.129 mol, 71%) as a tan crystalline solid. ESMS m/z 138 ($M+H$)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (s, 3H), 4.92 (m, 1H), 3.02-3.16 (m, 3H); elem. anal.: calc.: C 34.59; H 4.64; N 40.34; Cl 20.42 %, found: C 33.85, H 4.64, N 39.27, Cl 20.40 %; m.p. 166-167 °C; ee: 97%.

Example 2a: Synthesis of 1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (12a**)**




[00268] Using the procedure of Example 2, but starting with 2-*tert*-butoxycarbonylamino-pent-4-ynoic acid, afforded 1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (**12a**). ESMS m/z 138 ($M+H$)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (s, 3H), 4.92 (m, 1H), 3.02-3.16 (m, 3H).

Example 2b: Synthesis of (*R*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (12b**)**



[00269] Using the procedure of Example 2, but starting with (*R*)-2-*tert*-butoxycarbonylamino-pent-4-ynoic acid, affords (*R*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine hydrochloride (**12b**).

Example 3: Synthesis of (S)-3-(1-aminobut-3-ynyl)-1,2,4-oxadiazol-5(4H)-one hydrochloride (15)



Step 1: Synthesis of (S,Z)-tert-butyl 2-amino-1-hydroxyhex-1-en-5-yn-3-ylcarbamate (13)

[00270] To a stirred solution of (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester **10** (250 mg, 1.3 mmol) in ethanol (10 ml) was added 50% (w/w) aqueous hydroxylamine (0.36 ml, 5.15 mmol) and the reaction mixture was stirred for 18 h at room temperature. After completion of the reaction, the solvent was concentrated and the resulting residue was suspended in water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford (S,Z)-*tert*-butyl 2-amino-1-hydroxyhex-1-en-5-yn-3-ylcarbamate **13** in 96% yield. ¹H NMR (400 MHz, CDCl₃) δ 1.4(s, 9H), 2.5(brs, 2H), 2.8(s, 1H), 4.1 (t, 1H), 5.21 (s, 2H), 6.9(d, 1H), 9.1 (s, 1H).

Step 2: Synthesis of (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester (14)


[00271] To a stirred solution of (S,Z)-*tert*-butyl 2-amino-1-hydroxyhex-1-en-5-yn-3-ylcarbamate **13** (200 mg, 0.9 mmol) in tetrahydrofuran (5 ml) was added 1, 1'-carbonyldiimidazole (214 mg, 1.32 mmol) and the mixture was heated at reflux for 5 h under nitrogen atmosphere. After completion of the reaction mixture was cooled and solvent was concentrated under reduced pressure. The crude residue was dissolved in ethyl acetate and extracted with a 1M sodium hydroxide solution. The aqueous layer was diluted with dichloromethane, carefully acidified (pH~3-4) with 1M hydrochloric acid under cooling and extracted with dichloromethane. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and evaporated to afford (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester **14** in 45% yield. ¹H NMR (400 MHz, DMSO) δ 1.5 (s, 9H), 2.7 (d, 2H), 2.9 (s, 1H), 4.6 (d, 1H), 7.5 (d, 1H), 12.4(s, 1H). ESMS (negative mode): 252.15 (M-1).

Step 3: Synthesis of (S)-3-(1-aminobut-3-ynyl)-1,2,4-oxadiazol-5(4H)-one hydrochloride (15)

[00272] To a stirred solution of MeOH-HCl (6 ml) was added (S)-(1-cyano-but-3-ynyl)-carbamic acid *tert*-butyl ester **14** (90 mg, 0.35 mmol) and the resulting mixture was stirred for

12 h at room temperature. After completion of reaction, solvent was removed under reduced pressure, washed twice with ether and dried under reduced pressure to afford the desired product **6** in 59% yield as an off white solid. ^1H NMR (400 MHz, DMSO) δ 2.9 (brs, 2H), 3.22 (s, 1H), 4.61 (t, 1H), 9.0-10.1 (br s, 2H). ELSD Purity: 97.050%; ESMS (negative mode): 152.33 (M-1).

Example 4: Synthesis of (S)-1-(1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (20)



Step 1: Synthesis of (S)-tert-butyl 1-amino-1-thioxopent-4-yn-2-ylcarbamate (16)

[00273] To a stirred solution of (S)-tert-butyl 1-amino-1-oxopent-4-yn-2-ylcarbamate **9** (4.2 g, 19.7 mmol) in THF (40 ml), was added Lawesson's reagent (4 g, 9.8 mmol) and reaction mixture was heated at 50°C for 1 h. After completion of reaction, solvent was removed under reduced pressure and crude residue was purified by silica gel column chromatography (Ethyl acetate: Hexane = 1:2) to obtain (S)-tert-butyl 1-amino-1-thioxopent-4-yn-2-ylcarbamate (**16**) in 71% yield. ^1H NMR (400 MHz, CD_3OD) δ 1.4 (s, 9H), 2.7 (d, 2H), 2.9 (s, 1H), 4.4 (d, 1H), 6.8 (d, 1H), 9.2 (br s, 1H), 9.8 (br s, 1H).

Step 2: Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)pent-4-ynimidodithioate (17)

[00274] To a stirred solution of (S)-tert-butyl 1-amino-1-thioxopent-4-yn-2-ylcarbamate (**16**) (3.1 g, 13.5 mmol) in acetonitrile (25 ml) was added methyl iodide (9.6 g, 67.9 mmol) was added and the reaction mixture was heated at 50 °C for 1 h under nitrogen atmosphere. After completion of reaction, solvent was evaporated and the crude residue was washed with diethyl ether and dried to obtain (S)-methyl 2-(tert-butoxycarbonylamino)pent-4-ynimidodithioate (**17**) as a white solid in 88% yield. ESMS (positive mode): 243.15 (M+1).

Step 3: Synthesis of (S)-tert-butyl 1-(1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (19)


[00275] To a stirred solution of (S)-methyl 2-(tert-butoxycarbonylamino)pent-4-ynimidodithioate (**17**) (1 g, 4.12 mmol) and formyl hydrazide (**18**) (297 mg, 4.95 mmol) in ethanol (15 ml) was added diisopropylethyl amine (1.6 g, 12.3 mmol) and the reaction mixture was heated to reflux

for 4 h. After completion of reaction, solvent was removed under reduced pressure and the crude residue was purified by column chromatography (Ethyl acetate: Hexane = 1:1) to obtain (S)-*tert*-butyl 1-(1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**19**) in 21% yield. ¹H NMR (400 MHz, CDCl₃) δ 1.5 (s, 9H), 2.95 (br d, 2H), 5.1 (t, 1H), 5.6 (br s, 1H), 8.1 (br s, 1H), 11.8 (br s, 1H).

Step 4: Synthesis of (S)-1-(1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (20**)**

[00276] To a stirred solution of MeOH·HCl (10 ml), (S)-*tert*-butyl 1-(1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**19**) (200 mg, 0.847 mmol) was added and the resulting mixture was stirred for 12 h. After completion of reaction, solvent was removed under reduced pressure, washed twice with ether and dried under reduced pressure to afford (S)-1-(1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (**20**) in 89% yield as off white solid. ¹H NMR (400 MHz, DMSO) δ 2.9 (d, 2H), 3 (s, 1H), 4.6 (br s, 1H), 8.6 (s, 1H), 8.7 (br s, 2H). ELSD Purity: 98.95%; Mass (M+1): 137.1.

Example 5: Synthesis of (S)-1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (23**)**



Step 1: Synthesis of (S)-*tert*-butyl 1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (22**)**


[00277] To a stirred solution of (S)-methyl 2-(*tert*-butoxycarbonylamino)pent-4-ynimidothioate (**17**) (1 g, 4.1 mmol) and trifluoromethyl hydrazide (**21**) (0.634 g, 4.1 mmol) in ethanol (10 ml) was added diisopropylethyl amine (1.6 g, 12.3 mmol) and the reaction mixture was heated to reflux for 5 h. After completion of reaction, solvent was removed under reduced pressure and the crude residue was purified by column chromatography (Ethyl acetate: Hexane = 1:1) to obtain (S)-*tert*-butyl 1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**22**) 14% yield. ¹H NMR (400 MHz, CD₃OD) δ 1.5 (s, 9H), 2.0 (s, 1H), 2.9 (d, 2H), 5.0 (d, 1H), 5.5 (d, 1H).

Step 2: Synthesis of (S)-1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (23**)**

[00278] To a stirred solution of MeOH·HCl (5 ml), (S)-*tert*-butyl 1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**22**) (30 mg, 0.1 mmol) was added and the resulting mixture was stirred for 12 h at room temperature. After completion of reaction, solvent was

removed under reduced pressure, washed twice with ether and dried under reduced pressure to afford (S)-1-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)but-3-yn-1-amine hydrochloride (**23**) in 75% yield as off white solid. ¹H NMR (400 MHz, CD₃OD) δ: 2.6 (s, 1H), 3.1 (d, 2H), 4.8 (br s, 1H). ELSD Purity: 89.1%; ESMS: 204.06 (M⁺).

Example 6: Synthesis of (S)-5-(1-aminobut-3-ynyl)-1H-1,2,4-triazol-3-amine hydrochloride (27)



Step 1: Synthesis of (S)-tert-butyl 1-(imino(methylthio)methylamino)-1-oxopent-4-yn-2-ylcarbamate (25)

[00279] To a stirred solution of (S)-2-(tert-butoxycarbonylamino)pent-4-ynoic acid (**8**) (2.5 g, 11.7 mmol) in dichloromethane (25 ml) was added EDCI (2.72 g, 14.0 mmol), HOBT (1.24 g, 8.21 mmol), methyl carbamimidothioate hydroiodide (**24**) (2.55 g, 11.7 mmol), and DIPEA (6.13 ml, 35.2 mmole) and the reaction mixture was stirred at room temperature for 12 h under nitrogen atmosphere. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The crude residue was suspended in water and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product which was purified by silica gel column chromatography (EtOAc : Hexane = 2 : 3) to obtain (S)-tert-butyl 1-(imino(methylthio)methylamino)-1-oxopent-4-yn-2-ylcarbamate (**25**) in 60% yield as a pale yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 1.4 (s, 9H), 2.4 (s, 3H), 2.6-2.7 (m, 2H), 2.8 (s, 1H), 4.05 (s, 1H), 6.8 (d, 1H), 9.1 (br s, 2H). LCMS: 285 (M⁺+1).

Step 2: Synthesis of (S)-tert-butyl 1-(3-amino-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (26)


[00280] To a stirred solution of (S)-tert-butyl 1-(imino(methylthio)methylamino)-1-oxopent-4-yn-2-ylcarbamate (**25**) (1.2 g, 4.21 mmole) in ethanol (25 ml) was added hydrazine monohydrate (0.631 g, 12.6 mmole) and the reaction mixture was heated to reflux for 16 h under nitrogen atmosphere. After completion of the reaction, the reaction mixture was concentrated under

reduced pressure and the residue was suspended in water and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated to obtain crude product. The crude residue was purified by silica gel column chromatography (MeOH: dichloromethane = 1: 9) to afford (S)-*tert*-butyl 1-(3-amino-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**26**) in 12% yield as a white solid. ¹H NMR (400 MHz, DMSO) δ 1.4 (s, 9H), 2.6-2.8 (m, 3H), 4.5 (s, 1H), 5.8 (br s, 2H), 6.8 (br s, 1H), 11.8 (br s, 1H). LCMS: 252 (M^+ +1).

Step 3: Synthesis of (S)-5-(1-aminobut-3-ynyl)-1H-1,2,4-triazol-3-amine hydrochloride (27)

[00281] To a stirred solution of MeOH·HCl (5 ml) was added (S)-*tert*-butyl 1-(3-amino-1H-1,2,4-triazol-5-yl)but-3-ynylcarbamate (**26**) (30 mg, 0.119 mmol) and the resulting mixture was stirred for 12 h at room temperature. After completion of reaction, solvent was removed under reduced pressure, washed twice with ether and dried under reduced pressure to afford (S)-5-(1-aminobut-3-ynyl)-1H-1,2,4-triazol-3-amine hydrochloride (**27**) in 72% yield as an off white solid. ¹H NMR (400 MHz, DMSO) δ 2.8 (s, 2H), 3.05 (br s, 1H), 4.35-4.40 (m, 1H), 7.1-7.4 (br s, 2H), 8.7-8.8 (br s, 3H). HPLC Purity: 93.24%; LCMS: 152 (M^+ +1).

Example 7: Synthesis of (S)-2-amino-N-(2H-tetrazol-5-yl)pent-4-ynamide (29)



Step 1: Synthesis of (S)-*tert*-butyl 1-(2H-tetrazol-5-ylamino)-1-oxopent-4-yn-2-ylcarbamate (28)


[00282] To a solution of **8** (500 mg, 2.3 mmol) in anhydrous THF (5 mL) was added dropwise 4-methylmorpholine (0.27 mL, 2.8 mmol) followed by isobutyl carbonochloridate (0.23 mL, 2.8 mmol) at 0 °C. The suspension was stirred at the same temperature for 30 min prior to addition of 2H-tetrazol-5-amine (200 mg, 2.3 mmol). The mixture was allowed to stir at r.t. for 2 h, then diluted with ethyl acetate (10 mL) and water (15 mL) was added. The organic layer was separated and the aqueous layer was extracted two more times with ethyl acetate (10 mL). The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure to give **28** as a white solid (528 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ

1.38 (s, 9 H), 2.55 - 2.60 (m, 2 H), 2.91 (s, 1 H), 4.34 (d, $J = 6.8$ Hz, 1 H), 7.31 (d, $J = 6.8$ Hz, 1 H).

Step 2: Synthesis of (S)-2-amino-N-(2H-tetrazol-5-yl)pent-4-ynamide (29)

[00283] To a solution of **3** (528 mg, 1.9 mmol) in ethyl acetate (3 mL) was added a solution of HCl gas in ethyl acetate (3 mL, 4 N) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The resulting precipitate was collected by filtration, washed with ethyl acetate (10 mL) and dried to afford (S)-2-amino-N-(2H-tetrazol-5-yl)pent-4-ynamide (**29**) (100 mg) as a white solid. ^1H NMR (400 MHz, CD_3OD): δ 2.75 (t, $J = 2.6$ Hz, 1 H), 3.03 (dd, $J = 5.6$, 2.4 Hz, 2 H), 4.39 (t, $J = 6.2$ Hz, 1 H). LCMS (ESI): m/z 181.0 $[\text{M}+1]^+$.

Example 8: Synthesis of (S)-2-amino-N-(phenylsulfonyl)pent-4-ynamide hydrochloride (31)




Step 1: Synthesis of (S)-tert-butyl 1-oxo-1-(phenylsulfonylamino)pent-4-yn-2-ylcarbamate (30)

[00284] To a solution of **9** (2.0 g, 9.4 mmol) and benzenesulfonic acid (1.48 g, 9.4 mmol) in dry CH_2Cl_2 (20 mL) were added DMAP (1.15 g, 9.4 mmol) and EDCI (1.8 g, 9.4 mmol) at 0 °C. After stirring at room temperature for 3 h, the mixture was diluted with ethyl acetate, washed with water and brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue which was purified by flash column chromatography (PE / ethyl acetate = 10:1) to afford **30** (0.6 g) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ 1.46 (s, 9 H), 2.05 (d, $J = 1.8$ Hz, 1 H), 2.55 - 2.62 (m, 1 H), 2.68 - 2.74 (m, 1 H), 4.25 (br.s, 1 H), 5.21 (br.s, 1 H), 7.55 (t, $J = 7.8$ Hz, 2 H), 7.66 (t, $J = 7.9$ Hz, 1 H), 8.08 (d, $J = 3.8$ Hz, 2 H), 9.54 (br.s, 1 H).

Step 2: Synthesis of (S)-2-amino-N-(phenylsulfonyl)pent-4-ynamide hydrochloride (31)

[00285] 4 M HCl in ethyl acetate (10 mL) was added dropwise to a solution of **30** (600 mg, 1.7 mmol) in ethyl acetate (10 mL) at 0 °C and the reaction mixture was stirred at room temperature for 3 h. The precipitate was filtered, washed with ethyl acetate and dried under reduced pressure to afford (S)-2-amino-N-(phenylsulfonyl)pent-4-ynamide HCl salt (**31**) (393 mg) as a white solid. ^1H NMR (400 MHz, CD_3OD): δ 2.56 (t, $J = 2.6$ Hz, 1 H), 2.81 - 2.85 (m, 2 H), 4.05 (t, $J = 5.9$ Hz, 1 H), 7.61 (t, $J = 7.8$ Hz, 2 H), 7.72 (t, $J = 7.4$ Hz, 1 H), 8.06 (d, $J = 3.6$ Hz, 2 H).

Example 9: Synthesis of (S)-2-amino-N-(methylsulfonyl)pent-4-ynamide hydrochloride (33)



Step 1: Synthesis of (S)-tert-butyl 1-(methanesulfonyl)-1-oxopent-4-yn-2-ylcarbamate (32)

[00286] To a solution of **9** (2.0 g, 9.4 mmol) and methanesulfonic acid (0.91 g, 9.4 mmol) in dry CH_2Cl_2 (20 mL) were added DMAP (1.15 g, 9.4 mmol) and EDCI (1.8 g, 9.4 mmol). After stirring at room temperature for 3 h, the mixture was diluted with ethyl acetate, washed with water and brine, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash column chromatography (PE / Ethyl Acetate = 10:1) to afford **32** (1.2 g) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ 1.49 (s, 9 H), 2.16 (s, 1 H), 2.71 - 2.82 (m, 2 H), 3.31 (s, 3 H), 4.33 (m, 1 H), 5.28 (d, J = 7.6 Hz, 1 H), 9.35 (br.s, 1 H).

Step 2: Synthesis of (S)-2-amino-N-(methanesulfonyl)pent-4-ynamide hydrochloride (33)

[00287] 4 M HCl in ethyl acetate (10 mL) was added dropwise to a solution of **32** (765 mg, 2.63 mmol) in ethyl acetate (10 mL) at 0°C and the reaction mixture was stirred at room temperature for 3 h. The precipitate was filtered and washed with ethyl acetate to afford (S)-2-amino-N-(methanesulfonyl)pent-4-ynamide HCl salt (**33**) (450 mg) as a white solid. ^1H NMR (400 MHz, CD_3OD): δ 2.73 (t, J = 2.6 Hz, 1 H), 2.89 - 2.92 (m, 2 H), 3.28 (s, 3 H), 4.12 (t, J = 5.9 Hz, 1 H). LCMS (ESI): m/z 191.0 ($\text{M}+\text{H}$) $^+$.










Biological Examples

[00288] **Measurements of H_2S levels.** H_2S levels in the liver were assayed as follows. Briefly, liver tissue homogenates were prepared in 100 mM potassium phosphate buffer, pH 7.4 + 0.5% Triton-X100. The enzyme reaction was carried out in 96 well, deep square well plates with 700 μl Glass Insert (Waters Corporation Cat. #186000349) with TFE/Silicone MicroMat sealing covers (Sun-SRI Cat. #400 026). In the outer well in a total volume of 200 μl the assay mixture contained (in final concentration): L-cysteine, (5 mM); pyridoxal 5'-phosphate, (50 μM); potassium phosphate buffer, pH 7.4, (100 mM); and tissue homogenate (500 μg protein). The glass insert contained 100 μl alkaline zinc acetate solution (1% in 0.1N NaOH) to trap the generated H_2S . The reaction mixture was incubated at 37°C for 3 h and at the end of the reaction, 100 μl *N,N*-dimethyl-*p*-phenylenediamine sulfate (20 μM in 7N HCl) and 100 μl ferric chloride (30 μM in 1.2N HCl) was added to the glass insert. Absorbance was measured at 671 nm using a micro-plate reader. A standard curve relating the concentration of Na_2S and absorbance was used to calculate H_2S concentration and expressed as nanomoles of H_2S formed per hour per milligram protein.

Example 1: CSE *in vitro* assay

[00289] Test compounds (from DMSO stock solutions) were added to (final concentrations) 20 ug/ml enzyme solution (human, mouse or rat recombinant CSE) plus 50 uM PLP in assay buffer (100 mM potassium phosphate pH 7.6) in 96 well plates in total volume of 190 ul. Plates were incubated for 30 minutes at room temperature before the addition of 10 ul of 200 mM (20X final in assay buffer) DL-Homocysteine substrate to each well. Plates were incubated at 37 °C for 3 hours. 50 ul 20 mM DMPDA in 7.2N HCl was added to each well followed by 50 ul 30 mM FeCl₃ in 1.2N HCl. Plates were incubated for 10 minutes with shaking at room temperature and then absorbance at 671 nm read in Promega GloMax microplate reader.

Table 1

Example	Structure	IC ₅₀ (μM)	Example	Structure	IC ₅₀ (μM)
1		C	2		A
3		A	4		A
5		C	6		C
7		B	8		B
9		B			

IC₅₀ (μM) A < 25 μM; 25 μM ≤ B ≤ 100 μM; C > 100 μM

Table 2

Compound	IC50 (μM)
2-aminopent-4-ynoic acid	A
(S)-2-aminopent-4-ynoic acid	A
(R)-2-aminopent-4-ynoic acid	C
2-amino-3-cyanopropanoic acid	A

IC50 (μM) A < 25 μM; 25 μM ≤ B ≤ 100 μM; C > 100 μM

Example 2: Acute Post Surgical (Brennan) model of pain in the rat

[00290] The method, which detects antihyperalgesic activity in rats with postoperative pain, follows that described by Brennan et al (*Pain*, 64, 493-501, 1996).

[00291] Incision of the plantar face of the hindpaw in rats is associated with hyperalgesia, allodynia and spontaneous pain which lasts for 3 - 4 days, and therefore constitutes a model of postoperative pain in humans. Antihyperalgesics reduce these signs of acute pain hypersensitivity.

[00292] Rats were anesthetized with isoflurane and a 1 cm-longitudinal incision was made through skin, fascia and muscle of the plantar aspect of the left hindpaw. The wound was then sutured. After local application of antibiotic pomade, the rats were allowed to recover.

[00293] Test compounds were dosed two hours prior to pain testing (L-propargylglycine (L-PAG), 100 mpk IP; Compound A (Cmpd A), 300 mpk IP). Compound A is (S)-1-(1H-tetrazol-5-yl)-but-3-ynylamine.

Thermal hyperalgesia evaluation: Plantar test

[00294] For heat stimulation, the apparatus (Ugo Basile, Reference: 7371) consisted of individual acrylic plastic boxes (18 x 11.5 x 14 cm) placed upon an elevated glass floor. A rat was placed in the box and left free to habituate for 10 minutes. A mobile infrared radiant source (96 ± 10 mW/cm²) was focused under the non-incised and then under the incised hindpaw and the paw-withdrawal latency was automatically recorded. In order to prevent tissue damage the heat source was automatically turned off after 45 seconds (Fig. 1).

Tactile hyperalgesia evaluation: Pinchmeter test

[00295] The device consists of a pair of large blunt forceps (15 cm long; flat contact area: 7mm x 1.5 mm with smooth edges) equipped with 2 strain gauges connected to a modified electronic dynamometer. The tips of the forceps are placed around the hind paw of the tested animal and

the force applied is incremented by hand until the paw withdrawal response. The maximum force applied on the lesioned paw is automatically recorded and displayed by the dynamometer. In order to prevent tissue damage, the applied force is limited to a maximum of 1 kg. This procedure is carried out 3 times and the mean force per paw is calculated.

Example 3a: Chronic Constrictive Injury (Bennett) model of neuropathic pain in the rat

[00296] The method, which detects antihyperalgesic activity in rats with neuropathic pain, follows that described by Bennett and Xie (*Pain*, 33, 87-107, 1988).

[00297] Chronic constriction injury (CCI) of the common sciatic nerve in rats is associated with hyperalgesia, allodynia and spontaneous pain, and therefore constitutes a model for peripheral neuropathic pain in humans. Antihyperalgesics reduce these chronic signs of pain hypersensitivity.

[00298] Rats were anesthetized (sodium pentobarbital 40 mg/kg i.p.) and an incision at mid-thigh level was performed to expose the common left sciatic nerve. Four ligatures spaced 1 mm apart were loosely tied around the sciatic nerve. The wound was then sutured. The rats received a s.c. injection of Duphamox LA® and were allowed to recover.

[00299] Test compounds were dosed two hours prior to pain testing (L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; AMG-517; 3 mpk oral). Compound A is (S)-1-(1H-tetrazol-5-yl)-but-3-ynylamine. AMG-517 is N-[4-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-acetamide.

Tactile allodynia evaluation: electronic von Frey test

[00300] For tactile stimulation, the animal was placed under an inverted acrylic plastic box (18 x 11.5 x 14 cm) on a grid floor. The tip of an electronic von Frey probe was then applied with increasing force to the lesioned paw (2 hindpaws for the pre-test) and the force required to induce paw-withdrawal was automatically recorded. This procedure was carried out 3 times and the mean force per paw was calculated (Fig. 2).

Thermal hyperalgesia evaluation: Plantar test

[00301] For heat stimulation, the apparatus consists of individual acrylic plastic boxes (18 x 11.5 x 14 cm) placed upon an elevated glass floor. A rat was placed in the box and left free to habituate for 10 minutes. A mobile infrared radiant source was then focused under the lesioned hindpaw and the paw-withdrawal latency was automatically recorded. In order to prevent tissue damage the heat source was automatically turned off after 45 seconds (Fig. 3).

Tactile hyperalgesia evaluation: Pinchmeter test

[00302] The device consists of a pair of large blunt forceps (15 cm long; flat contact area: 7mm x 1.5 mm with smooth edges) equipped with 2 strain gauges connected to a modified electronic dynamometer. The tips of the forceps were placed around the hind paw of the tested animal and the force applied was incremented by hand until the paw withdrawal response. The maximum

force applied on the lesioned paw was automatically recorded and displayed by the dynamometer. In order to prevent tissue damage, the applied force was limited to a maximum of 1 kg. This procedure was carried out 3 times and the mean force per paw is calculated (Fig. 4).

Example 3b: Chronic Constrictive Injury (Bennett) model of neuropathic pain in the rat (alternate procedure)

[00303] Rats were anesthetized (2.5% Isoflurane) and an incision at mid-thigh level was performed to expose the common left sciatic nerve through the biceps femoralis muscle. Four chromic gut (3/0) ligatures spaced 1 mm apart were loosely tied around the sciatic nerve. The wound was then closed. The rats received a s.c. injection of amoxicillin (4 mg/kg) and were allowed to recover.

[00304] Test compounds were dosed one or six hours prior to pain testing. Compound A (Cmpd A), 1, 10, 100 mg/kg PO 6 hours pre test; Gabapentin; 300 mg/kg PO 1 hour pre test). Compound A is (*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine.

Tactile allodynia evaluation: electronic von Frey test

[00305] For tactile stimulation, the animal was placed under an inverted acrylic plastic box (18 x 11.5 x 14 cm) on a grid floor. The tip of an electronic von Frey probe was then applied with increasing force to the non lesioned and lesioned paws and the force required to induce paw-withdrawal was automatically recorded. This procedure was carried out 3 times on each paw and the mean difference in force that elicits withdrawal was calculated (Fig. 7).

Example 4a: Chronic Inflammatory Pain (Freund's adjuvant model) in the rat

[00306] The method, which detects analgesic/anti-inflammatory activity in rats suffering from acute inflammation, follows that described by Butler et al (*Pain*, 48, 73-81, 1992).

[00307] An intra- plantar injection of Freund's adjuvant in rats induces clinical signs of inflammation with pain.

[00308] On Day 0, rats were weighed and injected with a suspension of *Mycobacterium butyricum* (Freund's adjuvant) into the plantar surface of one hind paw (0.1 mg in 0.01 ml paraffin oil, 18μl). The other hind paw was injected with a corresponding volume of saline.

[00309] Test compounds were dosed two hours prior to pain testing (L-PAG, 100 mpk IP; Compound A (Cmpd A), 300 mpk IP; AMG-517; 3 mpk oral). Compound A is (*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine.

Tactile allodynia evaluation: electronic von Frey test

[00310] For tactile stimulation, the animal was placed under an inverted acrylic plastic box (18 x 11.5 x 14 cm) on a grid floor. The tip of an electronic von Frey probe was then applied with increasing force to the lesioned paw (2 hindpaws for the pre-test) and the force required to induce paw-withdrawal was automatically recorded. This procedure was carried out 3 times and the mean force per paw was calculated (Fig. 5).

Thermal hyperalgesia evaluation: Plantar test

[00311] For heat stimulation, the apparatus consists of individual acrylic plastic boxes (18 x 11.5 x 14 cm) placed upon an elevated glass floor. A rat was placed in the box and left free to habituate for 10 minutes. A mobile infrared radiant source was then focused first under the non-inflamed and then the inflamed hindpaw and the paw-withdrawal latency was automatically recorded. In order to prevent tissue damage the heat source was automatically turned off after 45 seconds (Fig. 6).

Example 4b: Chronic Inflammatory Pain (Freund's adjuvant model) in the rat (alternate procedure)

[00312] On Day 0, rats were weighed and injected with a suspension of *Mycobacterium butyricum* (Freund's adjuvant) into the plantar surface of one hind paw (0.1 mg in 0.01 ml paraffin oil, 18µl).

[00313] Test compounds were dosed two or six hours prior to pain testing. Compound A (Cmpd A), 1, 10, 100 mg/kg PO 6 hours pre test; Naproxen; 30 mg/kg PO 2 hour pre test). Compound A is (S)-1-(1H-tetrazol-5-yl)-but-3-ynylamine.

Tactile allodynia evaluation: electronic von Frey test

[00314] For tactile stimulation, the animal was placed under an inverted acrylic plastic box (18 x 11.5 x 14 cm) on a grid floor. The tip of an electronic von Frey probe was then applied with increasing force to the non lesioned and lesioned paws and the force required to induce paw-withdrawal was automatically recorded. This procedure was carried out 3 times on each paw and the mean difference in force that elicits withdrawal was calculated (Fig. 8).

Example 5: Arthritic Pain (Monosodium iodoacetate model (MIA)) in the rat

[00315] The method, which detects analgesic/anti-inflammatory activity in rats after induction of osteoarthritis, follows that described by Guingamp et al (Arthritis & Rheumatism, 40(9):1670-9, 1997).

[00316] An intra-articular injection of monosodium iodoacetate in rats induces clinical signs of inflammatory osteoarthritic pain.

[00317] On Day 0, rats were weighed and injected with a suspension of *monosodium iodoacetate* into the articular space of one knee (hindlimb) (2 mg in 0.04 ml saline).

[00318] Test compounds were dosed one or six hours prior to pain testing. Compound A (Cmpd A), 1, 10, 100 mg/kg PO 6 hours pre test; Gabapentin; 300 mg/kg PO 1 hour pre test). Compound A is (S)-1-(1H-tetrazol-5-yl)-but-3-ynylamine.

Tactile allodynia evaluation: electronic von Frey test

[00319] For tactile stimulation, the animal was placed under an inverted acrylic plastic box (18 x 11.5 x 14 cm) on a grid floor. The tip of an electronic von Frey probe was then applied with increasing force to the non lesioned and lesioned paws and the force required to induce paw-

withdrawal was automatically recorded. This procedure was carried out 3 times on each paw and the mean difference in force that elicits withdrawal is calculated (Fig. 9).

Example 6: CSE inhibition *in vivo* assay

Target Engagement

[00320] To evaluate *in vivo* CSE inhibition, male Sprague Dawley rats (approximately 300 grams) were orally dosed with 1, 3, 10, 30 mg/kg Compound A ((*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine) or vehicle (20% HP β CD in water). Two hours post dosing, animals were anesthetized with isoflurane and approximately 1 gram of liver tissue was removed, quickly rinsed in ice cold saline and homogenized in ice cold assay buffer (100 mM potassium phosphate, pH 7.6) plus 0.5% Triton X-100 using a BioSpec Products Tissue-Tearor. Samples were centrifuged for 30 minutes at 4°C at 20,000 X G and the supernatant was collected. Protein was determined by Pierce BCA assay using BSA as a standard.

[00321] Inhibition of CSE-mediated H₂S generation from cysteine was determined by incubating 200 μ g liver homogenate protein in assay buffer (100 mM potassium phosphate, pH 7.6) plus 10 mM L-cysteine and 50 μ M pyridoxal 5'-phosphate (200 μ l final volume) for 3 hours at 37°C in the outer well of 96-well deep well plates containing glass inserts (Waters #186000349) with 100 μ l of trapping solution (1% alkaline zinc acetate in 0.2N NaOH) to capture the liberated H₂S and sealed with TFE/silicone sealing mat (Sun SRI #400 026). The reaction was stopped and the H₂S that was generated was determined adding 100 μ l of 20 mM *N,N*-dimethyl-*p*-phenylenediamine sulphate in 7.2N HCl followed by addition of 100 μ l of 30 mM FeCl₃•6H₂O in 1.2N HCl. After mixing for 20 minutes at room temperature, 200 μ l of this solution was transferred to a standard 96-well clear bottom assay plate and absorbance at 671 nm was measured using a SpectraMax plate reader (Molecular Devices). Results were normalized to no lysate control level (Fig. 10).

Duration of Effect

[00322] To evaluate *in vivo* duration of effect of CSE inhibition, male Sprague Dawley rats (approximately 300 grams) were orally dosed with 30 mg/kg Compound A ((*S*)-1-(1*H*-tetrazol-5-yl)-but-3-ynylamine) or vehicle (20% HP β CD in water). Two, 24, 48, 72, 96, 120 or 144 hours post dosing animals were anesthetized with isoflurane and approximately 1 gram of liver tissue was removed, quickly rinsed in ice cold saline and homogenized in ice cold assay buffer (100 mM potassium phosphate, pH 7.6) plus 0.5% Triton X-100 using a BioSpec Products Tissue-Tearor. Samples were centrifuged for 30 minutes at 4°C at 20,000 X G and the supernatant was collected. Protein was determined by Pierce BCA assay using BSA as a standard.

[00323] Inhibition of CSE-mediated H₂S generated from cysteine was determined by incubating 200 µg liver homogenate protein in assay buffer (100 mM potassium phosphate, pH 7.6) plus 10 mM L-cysteine and 50 µM pyridoxal 5'-phosphate (200 µl final volume) for 3 hours at 37°C in the outer well of 96-well deep well plates containing glass inserts (Waters #186000349) with 100 µl of trapping solution (1% alkaline zinc acetate in 0.2N NaOH) to capture the liberated H₂S and sealed with TFE/silicone sealing mat (Sun SRI #400 026). The reaction was stopped and the H₂S that was generated was determined adding 100 µl of 20 mM *N,N*-dimethyl-*p*-phenylenediamine sulphate in 7.2N HCl followed by addition of 100 µl of 30 mM FeCl₃•6H₂O in 1.2N HCl. After mixing for 20 minutes at room temperature, 200 µl of the solution was transferred to a standard 96-well clear bottom assay plate and absorbance at 671 nm was measured using a SpectraMax plate reader (Molecular Devices). Results were normalized to no lysate control level (Fig. 11).

Example 7: A Study to Evaluate the Efficacy, Safety, and Tolerability of a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

[00324] The purpose of this study is to evaluate the safety and effectiveness of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) in the treatment of moderate to severe neuropathic pain in patients with a diagnosis of postherpetic neuralgia and post-traumatic neuralgia.

Condition	Intervention	Phase
Pain Neuralgia, Postherpetic Neuralgia Mononeuropathies	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) Drug: Placebo	Phase 2

[00325] Study Type: Interventional

[00326] Study Design:

[00327] Allocation: Randomized

[00328] Endpoint Classification: Safety/Efficacy Study

[00329] Intervention Model: Parallel Assignment

[00330] Masking: Double Blind (Subject, Investigator)

[00331] Primary Purpose: Treatment

[00332] Primary Outcome Measures:

[00333] The daily evening assessment of average pain intensity [Time Frame: Baseline (7 days before randomization) and last 7 days of the 12-week treatment phase] [Designated as safety issue: No]

[00334] Secondary Outcome Measures:

[00335] Pain at its worst [Time Frame: Daily for 12 weeks] [Designated as safety issue: No]

[00336] Brief Pain Inventory [Time Frame: Up to Week 13 (ie, at Visits 1, 3, 7, 8, 9)]
[Designated as safety issue: No]

[00337] Neuropathic pain symptom inventory [Time Frame: Up to Week 13 (ie, at Visits 1, 3, 7, 8, 9)] [Designated as safety issue: No]

[00338] Patient Global Impression of Change [Time Frame: Up to Week 13 (ie, at Visits 1, 3, 7, 8, 9)] [Designated as safety issue: No]

Arms	Assigned Interventions
Experimental: 001 Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) SC injection (1, 3 or 10 milligrams) once every 28 days	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
Placebo Comparator: 002 Placebo SC injection once every 28 days	Drug: Placebo Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks

[00339] Detailed Description:

[00340] The current study is a randomized (study drug assigned by chance), double-blind (neither the study doctor nor the patient knows the name of the assigned drug), placebo-controlled, dose-ranging study to evaluate the efficacy, safety, and tolerability of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) in patients with postherpetic neuralgia and post-traumatic neuralgia, followed by a double blind extension and an open-label (study doctor and patient knows the name of the study drug) extension. This study will evaluate the safety and effectiveness of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) in the treatment of patients with moderate to severe, chronic, neuropathic pain that is not controlled with or without standard pain therapy and who have a diagnosis of postherpetic neuralgia (PHN) or post-traumatic neuralgia. The total duration of the study will be approximately 130 weeks (i.e., includes screening phase, 12-week double-blind efficacy phase, double-blind safety extension

phase, and the open-label safety extension phase). During the 12 week treatment and 40 week double-blind extension phases, PHN patients will receive Placebo, a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 1, 3, or 10 mg and post-traumatic neuralgia patients will receive placebo or a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 10 mg; all doses will be given as a single, subcutaneous (under the skin) (SC) injection every 28 days. During the 52-week open-label extension phase, all patients will receive a single SC injection of a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) up to 10 mg every 4, 8, or 12 weeks.

[00341] *Eligibility*

[00342] Ages Eligible for Study: 18 Years to 80 Years

[00343] Genders Eligible for Study: Both

[00344] Accepts Healthy Volunteers: No

[00345] *Inclusion Criteria:*

[00346] Patients diagnosed with postherpetic neuralgia or post-traumatic neuralgia and who have chronic neuropathic pain (pain persistent for > 6 months) that is moderate to severe; currently taking pain medication but are not adequately controlled by standard of care or are not currently taking pain medications because intolerable to, or not willing to use, standard of care.

[00347] *Exclusion Criteria:*

[00348] History of a separate pain condition (e.g., joint osteoarthritis) that is more severe than pain due to diagnosis of PHN or post-traumatic neuralgia

[00349] Patients with post-traumatic neuralgia that are characteristic of complex regional pain syndrome Type I

[00350] Patients with lumbar-sacral radiculopathy, failed low-back surgery, or spinal cord injury

[00351] Patient whose nerve injury or pain is expected to recover in the next 4 months

[00352] Patients with evidence of another neuropathic pain not under study, such as pain resulting from diabetic painful neuropathy, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, HIV infection

[00353] Other peripheral neuropathy, paresthesia, or dysesthesia, or any other previously diagnosed neurologic condition causing the above noted symptoms that is not related with the PHN or post-traumatic neuralgia under the study

[00354] Women who are pregnant.

[00355] History of a separate pain condition (e.g., joint osteoarthritis) that is more severe than pain due to diagnosis of PHN or post-traumatic neuralgia; Patients with post-traumatic neuralgia that are characteristic of complex regional pain syndrome Type I; Patients with lumbar-sacral radiculopathy, failed low-back surgery, or spinal cord injury; Patient whose nerve injury or pain is expected to recover in the next 4 months; Patients with evidence of another neuropathic pain

not under study, such as pain resulting from diabetic painful neuropathy, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, HIV infection; Other peripheral neuropathy, paresthesia, or dysesthesia, or any other previously diagnosed neurologic condition causing the above noted symptoms that is not related with the PHN or post-traumatic neuralgia under the study; Women who are pregnant or breast-feeding; Type I or Type II diabetes.

Example 8: A Study Comparing the Efficacy and Safety of a Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) to Placebo in Subjects With Diabetic Neuropathic Pain

[00356] Purpose: To evaluate the safety and efficacy of a compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.

Condition	Intervention	Phase
Diabetic Neuropathic Pain	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 6 mg Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 12 mg Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 12 mg - 18 mg Drug: Placebo comparator Drug: Duloxetine	Phase 2

[00357] Study Type: Interventional

[00358] Study Design:

[00359] Allocation: Randomized

[00360] Endpoint Classification: Safety/Efficacy Study

[00361] Intervention Model: Parallel Assignment

[00362] Masking: Double Blind (Subject, Caregiver, Investigator)

[00363] Primary Purpose: Treatment

[00364] Primary Outcome Measures:

[00365] 24-hour Average Pain Score [Time Frame: 12 weeks] [Designated as safety issue: No]

[00366] Weekly mean of 24-hour average pain score measured by a 11-point Numeric Rating Scale completed on subject's daily diary.

[00367] Secondary Outcome Measures:

[00368] Neuropathic Pain Symptom Inventory [Time Frame: 12 weeks] [Designated as safety issue: No]

[00369] Measures severity of common neuropathic pain qualities (burning, pressure, squeezing)

[00370] Patient Global Impression of Change [Time Frame: 12 weeks] [Designated as safety issue: No]

[00371] Captures the subject's evaluation of his/her overall general impression of feeling since beginning study medication

[00372] Brief Pain Inventory [Time Frame: 12 weeks] [Designated as safety issue: No]

[00373] Capture the subject's severity of pain and interference

[00374] Neuropathic Pain Impact on Quality of Life Questionnaire [Time Frame: 12 weeks] [Designated as safety issue: No]

[00375] Captures the subject's assessment of neuropathic pain and the effect it has on the quality of daily life

[00376] EuroQuality of Life - 5 Dimension -5 Level [Time Frame: 12 weeks] [Designated as safety issue: No]

[00377] Capture's the subject's mobility, self-care, usual activity, pain/discomfort and anxiety/depression

Arms	Assigned Interventions
Experimental: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 6 mg Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) capsules - twice daily	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 6 mg See arm description for more information
Experimental: CSE Inhibitor 12 mg Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) capsules twice daily	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 12 mg See arm description for more information
Experimental: CSE Inhibitor 12 mg - 18 mg Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) capsules twice daily	Drug: Compound of Formula (I), (II), (IIa), (III), (IV), or (IVa) 12 mg - 18 mg See arm description for more information
Placebo Comparator: Placebo Placebo capsules twice daily	Drug: Placebo comparator See arm description for more information Other Name: Placebo
Active Comparator: Duloxetine	Drug: Duloxetine


Duloxetine capsules once daily	See arm description for more information
--------------------------------	--

[00378] *Eligibility***[00379]** Ages Eligible for Study: 18 Years to 75 Years**[00380]** Genders Eligible for Study: Both**[00381]** Accepts Healthy Volunteers: No**[00382]** *Inclusion Criteria***[00383]** Subject is between the ages of 18-75 years with a diagnosis of diabetes mellitus and must have a diagnosis of painful distal symmetric diabetic polyneuropathy and presence of ongoing pain due to diabetic peripheral neuropathy for at least 6 months.**[00384]** Subject must have a mean average score of greater than 4 on the 24 hour average pain score (0-10 numerical rating scale) prior to the Baseline Visit.**[00385]** Subject has been on a medication for diabetic neuropathic pain for the past 3 months.**[00386]** *Exclusion Criteria***[00387]** Subject has clinically symptomatic neuropathic pain conditions that cannot be distinguished from Diabetic Neuropathic Pain or interfere with the pain assessments of Diabetic Neuropathic Pain.**[00388]** A subject has newly diagnosed or clinically significant medical conditions or mental disorders that would preclude participation or would interfere with Diabetic Neuropathic Pain assessments or other functions.**[00389]** Subject has clinically significant abnormalities in clinical laboratory tests.**[00390]** Subject has taken an opioid chronically, excluding tramadol within the last 3 months prior to Screening.**[00391]** While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I) having the structure:



Formula (I);

wherein:

A is a carboxylic acid isostere;


X is CR₁, or N;

R₁ is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. A compound of Formula (II) having the structure:



Formula (II);

wherein:

A is a carboxylic acid isostere;


X is CR₁, or N;

R₁ is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;


R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

3. The compound of claim 1 or claim 2 wherein A is a carboxylic acid isostere selected from



4. The compound of claim 1 or claim 2 wherein A is a carboxylic acid isostere selected from -SO₃H, -SO₂NHR₄, -P(O)(OR₄)₂, -P(O)(R₄)(OR₄), -CON(R₄)₂, -CONHNHSO₂R₄, -CONHSO₂R₄, -B(OR₅)₂, -C(R₄)₂B(OR₅)₂, and -CON(R₄)C(R₄)₂B(OR₅)₂; wherein each R₄ is independently H, OH, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and R₅ is H or C₁-C₆alkyl.
5. The compound of any one of claims 1-4 wherein X is N.
6. The compound of any one of claims 1-4 wherein X is CR₁.
7. The compound of claim 6 wherein R₁ is H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
8. The compound of claim 7 wherein R₁ is H.
9. The compound of claim 7 wherein R₁ is CH₃.
10. A compound of Formula (III) having the structure:



Formula (III);


wherein:

A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

11. A compound of Formula (IV) having the structure:



Formula (IV);


wherein:


A is a carboxylic acid isostere;

R₂ and R₃ are each independently H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; or R₂ and R₃ together with the carbon to which they are attached form a cycloalkyl or heterocycloalkyl ring;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

12. The compound of claim 10 or claim 11 wherein A is a carboxylic acid isostere selected from





13. The compound of claim 10 or claim 11 wherein A is a carboxylic acid isostere selected from $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NHR}_4$, $-\text{P}(\text{O})(\text{OR}_4)_2$, $-\text{P}(\text{O})(\text{R}_4)(\text{OR}_4)$, $-\text{CON}(\text{R}_4)_2$, $-\text{CONHNHSO}_2\text{R}_4$, $-\text{CONHSO}_2\text{R}_4$, $-\text{B}(\text{OR}_5)_2$, $-\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$, and $-\text{CON}(\text{R}_4)\text{C}(\text{R}_4)_2\text{B}(\text{OR}_5)_2$; wherein each R_4 is independently H, OH, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and R_5 is H or $\text{C}_1\text{-C}_6$ alkyl.


14. The compound of any one of claims 1-13 wherein R_2 and R_3 are each H.

15. The compound of any one of claims 1-14 wherein A is .


16. The compound of any one of claims 1-14 wherein A is .

17. The compound of any one of claims 1-14 wherein A is .


18. The compound of claim 2 having the structure:



19. The compound of claim 2 having the structure:




20. The compound of claim 2 having the structure:



21. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of claims 1-20 or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a pharmaceutically acceptable prodrug thereof.
22. A method for treating or preventing or reducing the incidence of acute kidney injury (AKI) secondary to a toxic agent (e.g., cisplatin, aminoglycosides, and radiologic contrast material), nociceptive pain, acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, mixed neuropathic pain and inflammatory pain states, rheumatoid arthritis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, acute pancreatitis, chronic pancreatitis, pain associated with acute pancreatitis, pain associated with chronic pancreatitis, migraine headache, gout, ankylosing spondylitis, systemic lupus erythematosus (SLE), system inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), asthma, chronic obstructive pulmonary disease (COPD), sensitive skin, acne, rosacea, contact dermatitis, or pain associated with cancer, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of any one of claims 1-20 or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a pharmaceutically acceptable prodrug thereof.
23. The method of claim 22 for treating or preventing or reducing the incidence of acute post-operative pain, neuropathic pain, trigeminal neuralgia, diabetic peripheral neuropathy, herpetic neuralgia, post-herpetic neuralgia, inflammatory pain, rheumatoid arthritis, osteoarthritis, or migraine headache, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of any one of claims 1-20 or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a pharmaceutically acceptable prodrug thereof.
24. The method of claim 22 or 23, further comprising administration of a second agent selected from carbonic anhydrase inhibitors, cholinesterase inhibitors, adenosine inhibitors, progestational agents, opioid antagonists, central nervous system stimulants, selective serotonin reuptake inhibitors (SSRIs), dual 5-HT-NE reuptake inhibitors (SNRI's), antidepressants, antihypertensives, calcium channel antagonists, ACE inhibitors, respiratory stimulants, alpha-2 adrenergic agonists, gamma aminobutyric acid agonists, antiepileptic drugs, NSAIDs, steroids, and glutamate antagonists.
25. The method of claim 22 or 23, further comprising administration of a second agent selected from acetazolamide, theophylline, progesterone, donepezil, naloxone, nicotine, paroxetine, protriptyline, metoprolol, cilazapril, propranolol, atenolol, hydrochlorothiazide, isradipine, spirapril, doxapram, clonidine, baclofen, sabeluzole, gabapentin, pregablin, and duloxetine.


1/11

Fig. 1




2/11

Fig. 2




3/11

Fig. 3




4/11

Fig. 4




5/11

Fig. 5



6/11


Fig. 6



7/11


Fig. 7

CCI Tactile Allodynia




8/11

Fig. 8



9/11


Fig. 9

MIA Tactile Allodynia

10/11

Fig. 10


CSE Target Engagement



11/11

Fig. 11

CSE Duration of Effect



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/051744**A. CLASSIFICATION OF SUBJECT MATTER****C07D 257/04(2006.01)i, C07D 271/06(2006.01)i, A61K 31/41(2006.01)i, A61K 31/4245(2006.01)i, A61P 25/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 257/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: CSE, isostere

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KAWABATA, A. et al. 'Hydrogen sulfide as a novel nociceptive messenger' . Pain, 2007, Vol. 132, pages 74-81.	3-4, 18-20
A	See abstract .	12-13
Y	MITOS, C. 'Isosteres in medicinal chemistry' . Christos Mitsos Group Meeting, 2006.	3-4, 18-20
A	See page 4.	12-13
A	SUN, Q. et al. 'Structural basis for the inhibition mechanism of human cystathionine .gamma.-lyase, an enzyme responsible for the production of H ₂ S' . J. Biol. Chem., 2009, Vol. 284, pages 3076-3085.	3-4, 12-13, 18-20
A	See page 3077.	
A	EJIM, L. J. et al. 'Inhibitors of bacterial cystathionine .beta.-lyase: Leads for new antimicrobial agents and probes of enzyme structure and function' . J. Med. Chem., 2007, Vol. 50, pages 755-764.	3-4, 12-13, 18-20
A	See table 4.	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 November 2013 (28.11.2013)

Date of mailing of the international search report

28 November 2013 (28.11.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City,
302-701, Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

YOO, Jun Seok

Telephone No. +82-42-481-5782



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/051744

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 22-25
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 22-25 are directed to a treatment method of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required to search under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT.
2. ☒ Claims Nos.: 1-2,7-11
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
*Claims 1-2 and 10-11 are too broad to make meaningful search.
*Claims 7-9 refer to multiple dependent claims that refer to other multiple dependent claims, therefore, the meaning of the technical feature to which they refer is vague and unclear.
3. ☒ Claims Nos.: 5-6,14-17,21-25
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2013/051744Patent document
cited in search reportPublication
datePatent family
member(s)Publication
date

None